PUBLICACIONES

@article{deLacerda2026b,

title = {A new palladium(II) complex containing ethylenediamine and 2-thioxo-4-thiazolidinone exhibits high activity against resistant Campylobacter jejuni strains},

author = {Meiry Leandra de Lacerda and Letícia Roberta Martins Costa and Dayanne Maria da Silva Coimbra and Gabriele de Menezes Pereira and Clara Maria Faria Silva and Pedro Paulo Corbi and Daise Aparecida Rossi and Robson José de Oliveira Júnior and Roberta Torres de Melo and Wendell Guerra},

doi = {10.1016/j.ica.2025.122913},

issn = {0020-1693},

year  = {2026},

date = {2026-01-00},

urldate = {2026-01-00},

journal = {Inorganica Chimica Acta},

volume = {589},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Mastrobuono-Cordeiro2026,

title = {Synthesis, structural characterization and biological evaluation of silver(I) complexes with 2-thiouracil and 2,4-dithiouracil},

author = {Francisco Mastrobuono-Cordeiro and Julia H. Bormio Nunes and Gabriele de M. Pereira and Douglas H. Nakahata and Silmara C.L. Frajácomo and Wilton R. Lustri and João Ernesto de Carvalho and Douglas H. Pereira and Ana Lúcia T.G. Ruiz and Raphael E.F. de Paiva and Pedro P. Corbi},

doi = {10.1016/j.ica.2025.122971},

issn = {0020-1693},

year  = {2026},

date = {2026-01-00},

urldate = {2026-01-00},

journal = {Inorganica Chimica Acta},

volume = {590},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Coelho2025,

title = {Exploring biological properties of sulfa-based copper(II) complexes: in vitro genotoxicity, cytotoxicity (2D and 3D) and mechanistic insights},

author = {Maria Paula M. Coelho and Gabriele de Menezes Pereira and Pedro Paulo Corbi and Douglas H. Nakahata and Valentina Gandin and Chiara Donati and Juliana F. Vecina and Ana Lucia T. G. Ruiz},

doi = {10.1007/s10534-025-00719-0},

issn = {1572-8773},

year  = {2025},

date = {2025-10-00},

urldate = {2025-10-00},

journal = {Biometals},

volume = {38},

number = {5},

pages = {1551--1567},

publisher = {Springer Science and Business Media LLC},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Nakahata2025,

title = {Pd(II) complexes of 4-(2-aminoethyl)benzenesulfonamide Schiff bases: Structure, DNA binding and antiproliferative activity},

author = {Douglas H. Nakahata and Gabriele de M. Pereira and Marcos A. Ribeiro and Igor S. Oliveira and Josélia C. de Oliveira Moreira and Robson Pontes and João E. de Carvalho and Ana Lucia T.G. Ruiz and Nicholas P. Farrell and Pedro P. Corbi},

doi = {10.1016/j.ica.2025.122659},

issn = {0020-1693},

year  = {2025},

date = {2025-06-00},

urldate = {2025-06-00},

journal = {Inorganica Chimica Acta},

volume = {581},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Pereira2025,

title = {Evaluation of quality parameters, physicochemical and bioactive properties of licuri oil (Syagrus coronata)},

author = {Gabriel Sthefano Lourenço Pereira and Patrícia Tonon de Souza and Grace Kelly Mizuno Flozino and Rafael Fernandes Almeida and Dhayna Oliveira Sobral and Marcelo Antonio Morgano and Wilton Rogério Lustri and Silmara Cristina Lazarini and Pedro Paulo Corbi and Antonio José de Almeida Meirelles and Guilherme José Maximo and Eduardo Augusto Caldas Batista and Klicia Araujo Sampaio},

doi = {10.1016/j.foodres.2025.116157},

issn = {0963-9969},

year  = {2025},

date = {2025-05-00},

urldate = {2025-05-00},

journal = {Food Research International},

volume = {208},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Pereira2025b,

title = {Investigating the Antibacterial and Antitumoral Activities of New Copper(II) Complexes with Trifluoromethyluracil Isomers},

author = {Gabriele de Menezes Pereira and Julia Helena Bormio Nunes and Silmara Cristina Lazarini Frajácomo and Wilton Rogério Lustri and Fernando Rodrigues Goulart Bergamini and Josélia Cristina de Oliveira Moreira and Robson Pontes and Ana Lucia T. G. Ruiz and João Ernesto de Carvalho and Wdeson Pereira Barros and Pedro Paulo Corbi},

doi = {10.1002/slct.202405096},

issn = {2365-6549},

year  = {2025},

date = {2025-02-00},

urldate = {2025-02-00},

journal = {ChemistrySelect},

volume = {10},

number = {6},

publisher = {Wiley},

abstract = {<jats:title>Abstract</jats:title>

                  <jats:p>

                    New copper(II) complexes, derived from the isomers 5‐(trifluoromethyl)uracil (

                    <jats:bold>

                      L

                      <jats:sub>1</jats:sub>

                    </jats:bold>

                    ) and 6‐(trifluoromethyl)uracil (

                    <jats:bold>

                      L

                      <jats:sub>2</jats:sub>

                    </jats:bold>

                    ) with 2,2′‐bipyridine (

                    <jats:bold>Bpy</jats:bold>

                    ), [Cu(H

                    <jats:sub>2</jats:sub>

                    O)(L

                    <jats:sub>1</jats:sub>

                    )

                    <jats:sub>2</jats:sub>

                    Bpy] and [Cu(H

                    <jats:sub>2</jats:sub>

                    O)(L

                    <jats:sub>2</jats:sub>

                    )

                    <jats:sub>2</jats:sub>

                    Bpy], were synthesized, characterized, and evaluated for their antibacterial and antitumoral properties. Chemical analyses suggest the molecular formula CuC

                    <jats:sub>20</jats:sub>

                    H

                    <jats:sub>12</jats:sub>

                    F

                    <jats:sub>6</jats:sub>

                    N

                    <jats:sub>6</jats:sub>

                    O

                    <jats:sub>4</jats:sub>

                    ·H

                    <jats:sub>2</jats:sub>

                    O for both complexes. Infrared spectroscopic analyses indicate that trifluoromethyluracil isomers coordinate to copper(II) by the oxygen atoms. Structural confirmation of the [Cu(H

                    <jats:sub>2</jats:sub>

                    O)(L

                    <jats:sub>2</jats:sub>

                    )

                    <jats:sub>2</jats:sub>

                    Bpy] complex was obtained by single crystal X‐ray diffraction, where two L

                    <jats:sub>2</jats:sub>

                    molecules coordinate to the copper(II) ion by both oxygen atoms from carbonyl groups. The complexes demonstrated antibacterial activity against Gram‐positive

                    <jats:italic>Staphylococcus aureus</jats:italic>

                    and

                    <jats:italic>Bacillus cereus</jats:italic>

                    , and Gram‐negative

                    <jats:italic>Pseudomonas aeruginosa</jats:italic>

                    and

                    <jats:italic>Escherichia coli</jats:italic>

                    strains. The [Cu(H

                    <jats:sub>2</jats:sub>

                    O)(L

                    <jats:sub>1</jats:sub>

                    )

                    <jats:sub>2</jats:sub>

                    Bpy] complex exhibited the most promising results against

                    <jats:italic>P. aeruginosa</jats:italic>

                    , with a minimum inhibitory concentration (MIC) value of 0.478 mmol L

                    <jats:sup>−1</jats:sup>

                    . The [Cu(H

                    <jats:sub>2</jats:sub>

                    O)(L

                    <jats:sub>1</jats:sub>

                    )

                    <jats:sub>2</jats:sub>

                    Bpy] complex demonstrated antiproliferative effects on U251 and MCF‐7 cells, with GI

                    <jats:sub>50</jats:sub>

                    values (concentration that inhibits 50% of cell growth) of 2.18 ± 1.17 and 16.00 ± 10.07 µmol·L

                    <jats:sup>−1</jats:sup>

                    , whereas the [Cu(H

                    <jats:sub>2</jats:sub>

                    O)(L

                    <jats:sub>2</jats:sub>

                    )

                    <jats:sub>2</jats:sub>

                    Bpy] complex inhibited the growth of FaDu and U251 cells (GI

                    <jats:sub>50</jats:sub>

                    values 4.70 ± 2.69 µmol·L

                    <jats:sup>−1</jats:sup>

                    and 9.06 ± 3.86 µmol·L

                    <jats:sup>−1</jats:sup>

                    , respectively). Neither the precursors nor the copper(II) complexes affected the structure of CT‐DNA at the evaluated concentrations, suggesting that DNA is not the main cellular target of the complexes.

                  </jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{deAraujoFernandes2025,

title = {[99mTc]Technetium and Rhenium Dithiocarbazate Complexes: Chemical Synthesis and Biological Assessment},

author = {André Gustavo de Araujo Fernandes and Alyne Eloise Lafratta and Carolina Portela Luz and Debora Levy and Daniele de Paula Faria and Carlos Alberto Buchpiguel and Ulrich Abram and Victor Marcelo Deflon and Fabio Luiz Navarro Marques},

doi = {10.3390/pharmaceutics17010100},

issn = {1999-4923},

year  = {2025},

date = {2025-01-00},

urldate = {2025-01-00},

journal = {Pharmaceutics},

volume = {17},

number = {1},

publisher = {MDPI AG},

abstract = {<jats:p>Background/Objectives: Dithiocarbazates (DTCs) and their metal complexes have been studied regarding their property as anticancer activities. In this work, using S-benzyl-5-hydroxy-3-methyl-5-phenyl-4,5-dihydro-1H-pirazol-1-carbodithionate (H2bdtc), we prepared [ReO(bdtc)(Hbdtc)] and [[99mTc]TcO(bdtc)(Hbdtc)] complexes for tumor uptake and animal biodistribution studies. Methods: Re complex was prepared by a reaction of H2bdtc and (NBu4)[ReOCl4], the final product was characterized by IR, 1H NMR, CHN, and MS-ESI. 99mTc complex was prepared by the reaction of H2bdtc and [[99mTc]TcO4− and analyzed by planar and HPLC radiochromatography, and the stability was evaluated against amino acids and plasma. Biodistribution was performed in C57B/6 mice with B16F10 and TM1M implanted tumor. Results: Re is asymmetric coordinated by two dithiocarbazate ligands, one with O,N,S chelation, and the other with N,S chelation; [[99mTc]TcO(bdtc)(Hbdtc)] was prepared with a radiochemical yield of around 93%. The radioactive complex is hydrophobic (LogP = 1.03), stable for 6 h in PBS and L-histidine solution; stable for 1 h in plasma, but unstable in the presence of L-cysteine. Ex vivo biodistribution demonstrated that the compound has a fast and persistent (until 2 h) uptake by the spleen (55.46%), and tumor B16F10 and TM1M uptake is lower than 1%. In vivo SPECT/CT imaging confirmed ex vivo biodistribution, except by heterogenous TM1M accumulation but not in the B16-F10 lineage. Conclusions: H2bdtc proved to be an interesting chelator for rhenium or [99mTc]technetium. The right spleen uptake opened the opportunity to deepen the study of the molecule in this tissue and justifies future studies to identify the reason of heterogenous uptake in TM1M tumor uptake.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{P.dosSantos2025,

title = {High Selective N-Acylhydrazones Silver(I) Complexes against Tuberculosis},

author = {Paulo Victor P. dos Santos and Nícolas Glanzmann and Adilson D. da Silva and Fernando R. Pavan and Christian S. C. Canales and Cesar A. Roque‑Borda and Pedro P. Corbi and Douglas H. Pereira and Kaíque A. D'Oliveira and Alexandre Cuin},

doi = {10.21577/0103-5053.20250093},

issn = {1678-4790},

year  = {2025},

date = {2025-00-00},

urldate = {2025-00-00},

journal = {J. Braz. Chem. Soc.},

publisher = {Sociedade Brasileira de Quimica (SBQ)},

abstract = {<jats:p>In the present work, synthesis, characterization, and biological assays of seven N-acylhydrazones

derivatives of isoniazid and their corresponding silver(I) complexes are described. The compounds

were characterized by elemental analysis, infrared (IR) and 1 H, 13C and 1

H-15N nuclear magnetic

resonance (NMR) spectroscopic measurements, and molar conductivity over 48 h assays. Density

functional theory (DFT) studies also were employed in order to structural elucidation of the

seven silver(I) complexes. All the synthesized silver complexes have shown minimum inhibitory

concentration (MIC90) values against Mycobacterium tuberculosis - MtbH37Rv (ATCC 27294)

lower than 7.421 mg L–1. The AgIZBEN complex showed the most promising anti-tuberculosis

action, with MIC90 of 0.956 mg L–1 and selectivity index (SI) = 29.3 while the AgIZpAN showed

SI higher than 460 and MIC90 of 1.077 mg L–1. The free acylhydrazones derivatives also showed

SI higher than 20.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{A.D'Oliveira2025,

title = {Silver-dichloroquinoline Complexes: Synthesis, Structure and Antitubercular Properties},

author = {Kaíque A. D'Oliveira and Nícolas Glanzmann and Adilson D. da Silva and Carlos E. T. Bruzeguini and Marcos A. Ribeiro and Christian S. C. Canales and Cesar A. Roque-Borda and Fernando R. Pavan and Pedro P. Corbi and Norberto Masciocchi and Alexandre Cuin},

doi = {10.21577/0103-5053.20250048},

issn = {1678-4790},

year  = {2025},

date = {2025-00-00},

urldate = {2025-00-00},

journal = {J. Braz. Chem. Soc.},

publisher = {Sociedade Brasileira de Quimica (SBQ)},

abstract = {<jats:p>Synthesis, characterization, and antitubercular activity of three silver(I) complexes

with 4,7-dichloroquinoline (C9H5Cl 2N, DCQ), 2,2’-bipyridine (C10H8N2, Bpy)

and triphenylphosphine (C18H15P, PPh3) are presented. Complex 1 was formulated as

[Ag(H2O)(DCQ)2(μ-ONO2)Ag(NO3)(DCQ)2], 1:2 M:L1 molar ratio, L1 = DCQ. Complexes 2

[Ag(NO3)(DCQ)(Bpy)] and 3 [Ag(NO3)(DCQ)(PPh3)]2 exhibit 1:1:1 M:L1:L2 molar ratio, where

L2 = Bpy or PPh3. All compounds were analytically, spectroscopically, and structurally

characterized. The crystal and molecular structures of complexes 1 and 3 were determined by

conventional single-crystal X-ray diffraction, while the crystal structure of 2 was elucidated using

laboratory powder diffraction method. Elemental analyses, conductometry, infrared (IR), Raman,

UV-Vis, and 1

H, 13C{1

H}, 31P{1

H}, {1

H-15N} heteronuclear multiple bond correlation (HMBC)

nuclear magnetic resonance (NMR) spectroscopies, along with 1

H NMR T1 relaxation time

measurements, corroborate the proposed formulas. Complex 3, in the solid state, was found to

contain significant residual solvents (CH3OH and CH3CN). Consequently, its desolvation process

was investigated using IR microscopy and X-ray powder diffraction. In vitro biological assays

against Mycobacterium tuberculosis H37Rv (ATCC 27294) were performed for all compounds.

Complexes 1 and 3 shown the lowest concentration of the antibiotic at which 90% of the isolates

are inhibited (MIC90) of 7 ± 1 and 14 ± 3 µg mL–1, suggesting their potential as antimycobacterial

agents, in contrast, assays indicate lower activity for compound 2 against the evaluated strains.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Rezende2024,

title = {Coordination Compounds as Antivirals against Neglected Tropical Diseases},

author = {Wallace S. Rezende and Antonio Marçal Neto and Juliano J. Corbi and Pedro P. Corbi and Raphael E. F. de Paiva and Fernando R. G. Bergamini},

doi = {10.1002/cmdc.202400799},

issn = {1860-7187},

year  = {2024},

date = {2024-12-09},

urldate = {2024-12-09},

journal = {ChemMedChem},

publisher = {Wiley},

abstract = {<jats:title>Abstract</jats:title><jats:p>Neglected tropical viral diseases are a burden to social and economic welfare being responsible for higher pathogen‐related mortality rates and chronic debilitating patient conditions. Climatic changes have widened up the infectibility ratio of such diseases, with autochthonous transmission in formerly temperate‐to‐cold environments. The slow‐paced development of potential vaccines followed by the inexistence of antiviral drugs for such diseases considerably worsens the situation. Coordination compounds are a class of molecules that have been extensively explored as antiviral drugs for viruses such as poliovirus, HIV and, more recently, SARS‐CoV‐2, figuring as potential molecules to be explored and capitalized as antivirals against neglected viral strains. In this review the current efforts from the inorganic medicinal chemistry to address viral neglected tropical diseases, with emphasis to coordination compounds, is presented. Since many of neglected viruses are also arthropod‐borne viruses, relying on a vector for transmission, coordination entities able to mitigate vectors are also presented as a parallel strategy to prevent and control such diseases.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Mendonça2024d,

title = {Assessment of bioactive peptides derived from laminin-111 as prospective breast cancer-targeting agents},

author = {Fernanda Ferreira Mendonça and Danielle Vieira Sobral and Ana Claudia Ranucci Durante and Ana Cláudia Camargo Miranda and Jorge Mejia and Daniele de Paula Faria and Fabio Luiz Navarro Marques and Marycel Figols de Barboza and Leonardo Lima Fuscaldi and Luciana Malavolta},

doi = {10.1007/s00726-023-03379-x},

issn = {1438-2199},

year  = {2024},

date = {2024-12-00},

urldate = {2024-12-00},

journal = {Amino Acids},

volume = {56},

number = {1},

publisher = {Springer Science and Business Media LLC},

abstract = {<jats:title>Abstract</jats:title><jats:p>Breast cancer remains a pressing public health issue primarily affecting women. Recent research has spotlighted bioactive peptides derived from laminin-111, implicated in breast tumor development. Remarkably, the sequences IKVAV, YIGSR, and KAFDITYVRLKF from the α1, β1, and γ1 chains, respectively, have garnered significant attention. This study aims to assess the potential of these radiolabeled peptides as targeting agents for breast cancer. The three peptides were synthesized using the Fmoc strategy, purified via reversed-phase high-performance liquid chromatography (RP-HPLC), and characterized through mass spectrometry. Iodine-131 (<jats:sup>131</jats:sup>I) radiolabeling was performed using the chloramine T method, exhibiting high radiochemical yield and stability for [<jats:sup>131</jats:sup>I]I-YIKVAV and [<jats:sup>131</jats:sup>I]I-YIGSR. Conversely, [<jats:sup>131</jats:sup>I]I-KAFDITYVRLKF demonstrated low radiochemical yield and stability and was excluded from the biological studies. The lipophilicity of the compounds ranged from − 2.12 to − 1.10. Serum protein binding assay for [<jats:sup>131</jats:sup>I]I-YIKVAV and [<jats:sup>131</jats:sup>I]I-YIGSR reached ≅ 48% and ≅ 25%, respectively. Affinity for breast cancer cells was evaluated using MDA-MB-231 and MCF-7 tumor cell lines, indicating the affinity of the radiopeptides with these tumor cells. Ex vivo biodistribution profiles of the radiopeptides were assessed in the MDA-MB-231 breast tumor animal model, revealing tumor tissue accumulation, supported by a high tumor-to-contralateral muscle ratio and autoradiography. These results signify the effective penetration of YIKVAV and YIGSR into tumor tissue. Therefore, the synthesized α1 and β1 peptide fragments exhibit favorable characteristics as potential breast cancer-targeting agents, promising future exploration as radiopharmaceuticals for breast cancer.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Machado2024,

title = {A New Heteroleptic Zn(II) Complex with Schiff Bases Sensitizes Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel},

author = {Raiane Aparecida dos Santos Machado and Raoni Pais Siqueira and Fernanda Cardoso da Silva and André Carlos Pereira de Matos and Dayanne Silva Borges and Gislaine Gonçalves Rocha and Thais Cristina Prado de Souza and Rafael Aparecido Carvalho Souza and Clayton Rodrigues de Oliveira and Antônio G. Ferreira and Pedro Ivo da Silva Maia and Victor Marcelo Deflon and Carolina Gonçalves Oliveira and Thaise Gonçalves Araújo},

doi = {10.3390/pharmaceutics16121610},

issn = {1999-4923},

year  = {2024},

date = {2024-12-00},

urldate = {2024-12-00},

journal = {Pharmaceutics},

volume = {16},

number = {12},

publisher = {MDPI AG},

abstract = {<jats:p>Background/Objectives: Triple-negative breast cancer (TNBC) is the most challenging molecular subtype of breast cancer (BC) in clinical practice, associated with a worse prognosis due to limited treatment strategies and its insensitivity to conventional drugs. Zinc is an important trace element for homeostasis, and its Schiff base metal complexes have shown promise in treating advanced tumors. In this study, four new heteroleptic Zn(II) complexes (1–4) with Schiff bases were synthesized, characterized, and evaluated for their activity in BC cells. Methods: Compounds were synthesized, characterized, and their crystal structures were determined. Biological activity was assessed using MTT, clonogenic, scratch wound healing, caspase 3 and 8 activity, qPCR, and chemosensitization assays. Results: The complexes exhibited cytotoxicity against MCF-7 (luminal BC), MDA-MB-453 (HER2-positive BC), and MDA-MB-231 (TNBC) cell lines, with IC50 values ranging from 0.01 to 20 µM. Complex 4 showed reduced cytotoxicity toward non-tumor cell lines. This, complexation with Zn(II) increased the cytotoxicity of the ligands, a trend not observed for complexes 1–3. Due to its favorable profile, complex 4 was selected for further assays, in which it inhibited colony formation and the cell migration of TNBC cells in a dose-dependent manner. Furthermore, this compound induced cell death independently of caspases, decreasing the activity of caspase 8. Interestingly, complex 4 sensitized TBNC cells to doxorubicin and paclitaxel, possibly modulating the epithelial–mesenchymal transition mechanism, as evidenced by increased CDH1 expression. Conclusions: Results suggest the potential of complex 4 in sensitizing aggressive BC cells to chemotherapy, proving to be a promising alternative in cases of therapeutic failure.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Silva2024b,

title = {Antiviral Activity of Pd(II) Complexes with Aminoadamantanes Against Arboviruses},

author = {Laura Barros Silva and Állefe Barbosa Cruz and Douglas Henrique Pereira and Natasha Marques Cassani and Uriel Enrique Aquino Ruiz and Igor Andrade Santos and Daniel Oliveira Silva Martins and Douglas Hideki Nakahata and Déborah de Alencar Simoni and Ioannis Kanavos and Luisa Ronga and Ryszard Lobinski and Anna Karla dos Santos Pereira and Ana Carolina Gomes Jardim and Raphael Enoque Ferraz de Paiva and Pedro Paulo Corbi},

doi = {10.1002/slct.202404225},

issn = {2365-6549},

year  = {2024},

date = {2024-10-04},

urldate = {2024-10-04},

journal = {ChemistrySelect},

volume = {9},

number = {37},

publisher = {Wiley},

abstract = {<jats:title>Abstract</jats:title>

                  <jats:p>

                    In this paper, we report the synthesis, structural characterization, and antiviral properties of palladium(II) complexes with amantadine (atd) and memantine (mtn). Elemental and mass spectrometric analyses indicated a 1:2 metal/ligand ratio. The single crystal data for Pd‐mtn revealed that the complex adopts a square geometry with the two memantine ligands bonded to Pd(II) by the nitrogen atoms of the NH

                    <jats:sub>2</jats:sub>

                    group, in a

                    <jats:italic>trans</jats:italic>

                    configuration. Computational studies supported a similar structure for Pd‐atd. The complexes were stable in DMSO solution for 24 h. The antiviral properties of Pd‐atd and Pd‐mtn were evaluated against

                    <jats:italic>Zika</jats:italic>

                    (ZIKV) and

                    <jats:italic>Chikungunya</jats:italic>

                    (CHIKV)

                    <jats:italic>viruses</jats:italic>

                    in vitro at their highest noncytotoxic concentrations. The Pd‐atd (at 2 µM) and Pd‐mtn (at 10 µM) complexes were able to impair 76% and 96% of CHIKV replication, respectively, which points the coordination of amantadine and memantine to Pd(II) as a successful strategy to increase their anti‐CHIKV properties. Conversely, the Pd(II) complexes did not significantly inhibit the replication of ZIKV, which confirms the selectivity towards CHIKV. Interaction of the compounds with

                    <jats:italic>N</jats:italic>

                    ‐acetyl‐

                    <jats:sc>l</jats:sc>

                    ‐cysteine, a model disulfide‐containing peptide, and plasmid DNA pointed to Cys‐containing peptides as more likely targets than nucleotides for the complexes.

                  </jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Martins2024,

title = {Exploring the antiviral activities of the FDA-approved drug sulfadoxine and its derivatives against Chikungunya virus},

author = {Daniel Oliveira Silva Martins and Uriel Enrique Aquino Ruiz and Igor Andrade Santos and Igor Santos Oliveira and Marco Guevara-Vega and Raphael Enoque Ferraz de Paiva and Camilla Abbehausen and Robinson Sabino-Silva and Pedro Paulo Corbi and Ana Carolina Gomes Jardim},

doi = {10.1007/s43440-024-00635-z},

issn = {2299-5684},

year  = {2024},

date = {2024-10-00},

urldate = {2024-10-00},

journal = {Pharmacol. Rep},

volume = {76},

number = {5},

pages = {1147--1159},

publisher = {Springer Science and Business Media LLC},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RodriguesToledo2024,

title = {EGFR- and Integrin αVβ3-Targeting Peptides as Potential Radiometal-Labeled Radiopharmaceuticals for Cancer Theranostics},

author = {Cibele Rodrigues Toledo and Ahmed A. Tantawy and Leonardo Lima Fuscaldi and Luciana Malavolta and Carolina de Aguiar Ferreira},

doi = {10.3390/ijms25158553},

issn = {1422-0067},

year  = {2024},

date = {2024-08-00},

urldate = {2024-08-00},

journal = {IJMS},

volume = {25},

number = {15},

publisher = {MDPI AG},

abstract = {<jats:p>The burgeoning field of cancer theranostics has witnessed advancements through the development of targeted molecular agents, particularly peptides. These agents exploit the overexpression or mutations of specific receptors, such as the Epidermal Growth Factor receptor (EGFR) and αVβ3 integrin, which are pivotal in tumor growth, angiogenesis, and metastasis. Despite the extensive research into and promising outcomes associated with antibody-based therapies, peptides offer a compelling alternative due to their smaller size, ease of modification, and rapid bioavailability, factors which potentially enhance tumor penetration and reduce systemic toxicity. However, the application of peptides in clinical settings has challenges. Their lower binding affinity and rapid clearance from the bloodstream compared to antibodies often limit their therapeutic efficacy and diagnostic accuracy. This overview sets the stage for a comprehensive review of the current research landscape as it relates to EGFR- and integrin αVβ3-targeting peptides. We aim to delve into their synthesis, radiolabeling techniques, and preclinical and clinical evaluations, highlighting their potential and limitations in cancer theranostics. This review not only synthesizes the extant literature to outline the advancements in peptide-based agents targeting EGFR and integrin αVβ3 but also identifies critical gaps that could inform future research directions. By addressing these gaps, we contribute to the broader discourse on enhancing the diagnostic precision and therapeutic outcomes of cancer treatments.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Candido2024,

title = {Crystal Structure and Anti-Proliferative and Mutagenic Evaluation of the Palladium(II) Complex of Deoxyalliin},

author = {Tuany Zambroti Candido and Mariana Mazzo Quintanilha and Bianca Alves Schimitd and Déborah de Alencar Simoni and Douglas Hideki Nakahata and Raphael Enoque Ferraz de Paiva and Igor Henrique Cerqueira and Flávia Aparecida Resende and João Ernesto Carvalho and Ana Lucia Tasca Gois Ruiz and Carmen Silvia Passos Lima and Pedro Paulo Corbi},

doi = {10.3390/inorganics12070194},

issn = {2304-6740},

year  = {2024},

date = {2024-07-00},

urldate = {2024-07-00},

journal = {Inorganics},

volume = {12},

number = {7},

publisher = {MDPI AG},

abstract = {<jats:p>Platinum(II) and palladium(II) complexes have been investigated as potential anticancer drugs since the serendipitous discovery of the antineoplastic activities of cisplatin in the 1960s. Skin cancer is considered the most common malignant neoplasm that affects humans, and melanoma is the most lethal type of skin cancer. Surgical excision is the main form of treatment, which also may include radiotherapy, systemic chemotherapy, and immunotherapy. In this work, new insights concerning the structural characterization and in vitro anti-proliferative activity of the palladium(II) complex with the amino acid deoxyalliin (Pd-sac) against a panel of thirteen human tumor cells, with emphasis on skin cancer cell lines, are presented. The composition of the complex was confirmed by elemental analysis as [Pd(C6H10NO2S)2]. The structure of the complex was elucidated for the first time by a single-crystal X-ray diffraction technique. Each deoxyalliin molecule coordinates in a bidentate N,S-mode to palladium(II) in a trans-configuration analogous to the platinum(II) deoxyalliin complex early reported. As the main result, the Pd-sac complex showed a selective anti-proliferative activity against melanoma (UACC-62, TGI = 63.5 µM), while both deoxyalliin and K2PdCl4 were inactive against all cell lines. Moreover, Pd-sac did not affect the proliferation of non-tumorigenic keratinocytes (HaCaT, TGI > 586 µM) and was non-mutagenic in the Ames assay. The results open new perspectives for in vivo studies concerning the application of the Pd-sac complex in the treatment of melanoma.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Marinho2024,

title = {Development and validation of Mayaro virus with luciferase reporter genes as a tool for antiviral assays},

author = {Mikaela dos Santos Marinho and Ya-Nan Zhang and Natasha Marques Cassani and Igor Andrade Santos and Ana Laura Costa Oliveira and Anna Karla dos Santos Pereira and Pedro Paulo Corbi and Bo Zhang and Ana Carolina Gomes Jardim},

doi = {10.1016/j.heliyon.2024.e33885},

issn = {2405-8440},

year  = {2024},

date = {2024-07-00},

urldate = {2024-07-00},

journal = {Heliyon},

volume = {10},

number = {13},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Ferreira2024,

title = {A new copper(II) complex containing long-chain aliphatic hydrazide and 1,10-phenanthroline upregulates ADP hydrolysis in triple-negative breast cancer cells},

author = {Helen Soares Valença Ferreira and Luana Munique Sousa Ramos and Fernanda Cardoso Silva and Daniel Lima Alves and Gabriele de Menezes Pereira and Pedro Henrique de Oliveira Santiago and Angelina Maria de Almeida and Javier Ellena and Pedro Paulo Corbi and Carolina Gonçalves Oliveira and Mauro Vieira de Almeida and Cristina Ribas Fürstenau and Dayanne Silva Borges and Raoni Pais Siqueira and Wendell Guerra and Thaise Gonçalves Araújo},

doi = {10.1016/j.jinorgbio.2024.112524},

issn = {0162-0134},

year  = {2024},

date = {2024-06-00},

urldate = {2024-06-00},

journal = {Journal of Inorganic Biochemistry},

volume = {255},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Borges2024,

title = {Gold(I) and Silver(I) Complexes Containing Hybrid Sulfonamide/Thiourea Ligands as Potential Leishmanicidal Agents},

author = {Alice P. Borges and Malu M. S. Obata and Silvia H. Libardi and Rafael O. Trevisan and Victor M. Deflon and Ulrich Abram and Francis B. Ferreira and Luiz Antônio S. Costa and Antonio O. T. Patrocínio and Marcos V. da Silva and Júlio C. Borges and Pedro I. S. Maia},

doi = {10.3390/pharmaceutics16040452},

issn = {1999-4923},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Pharmaceutics},

volume = {16},

number = {4},

publisher = {MDPI AG},

abstract = {<jats:p>Leishmaniasis is a group of parasitic diseases with the potential to infect more than 1 billion people; however, its treatment is still old and inadequate. In order to contribute to changing this view, this work consisted of the development of complexes derived from MI metal ions with thioureas, aiming to obtain potential leishmanicidal agents. The thiourea ligands (HLR) were obtained by reactions of p-toluenesulfohydrazide with R-isothiocyanates and were used in complexation reactions with AgI and AuI, leading to the formation of complexes of composition [M(HLR)2]X (M = Ag or Au; X = NO3− or Cl−). All compounds were characterized by FTIR, 1H NMR, UV-vis, emission spectroscopy and elemental analysis. Some representatives were additionally studied by ESI-MS and single-crystal XRD. Their properties were further analyzed by DFT calculations. Their cytotoxicity on Vero cells and the extracellular leishmanicidal activity on Leishmania infantum and Leishmania braziliensis cells were evaluated. Additionally, the interaction of the complexes with the Old Yellow enzyme of the L. braziliensis (LbOYE) was examined. The biological tests showed that some compounds present remarkable leishmanicidal activity, even higher than that of the standard drug Glucantime, with different selectivity for the two species of Leishmania. Finally, the interaction studies with LbOYE revealed that this enzyme could be one of their biological targets.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Amaral2024c,

title = {Synthesis, spectroscopic and structural characterizations and in vitro antimycobacterial activity of silver(I) complexes with sulfapyridine (SPY) and sulfamerazine (SM)},

author = {Thaeny Costa Amaral and Nícolas Glanzmann and Adilson D. da Silva and Gabriele de M. Pereira and Pedro P. Corbi and Christian S.C. Canales and Fernando R. Pavan and Kaíque A.D. Oliveira and Alexandre Cuin},

doi = {10.1016/j.molstruc.2023.137234},

issn = {0022-2860},

year  = {2024},

date = {2024-03-00},

urldate = {2024-03-00},

journal = {Journal of Molecular Structure},

volume = {1300},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Teixeira2024,

title = {New binuclear copper(I) complexes with dual bioactivity: Synthesis, structural characterization and biological assays against bacteria and cancer},

author = {Cristiane F.A. Teixeira and Estefane I. Teixeira and J.P.C. Nascimento and Amilcar M. Júnior and L.M.C. Pinto and Anderson R.L. Caires and G.B. Alcantara and Ana C. Micheletti and Victor M. Deflon and Davi F. Back and Heveline Silva and Lucas Pizzuti and Gleison Antônio Casagrande},

doi = {10.1016/j.ica.2023.121818},

issn = {0020-1693},

year  = {2024},

date = {2024-01-00},

urldate = {2024-01-00},

journal = {Inorganica Chimica Acta},

volume = {560},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Cerqueira2024,

title = {EVALUATION OF THE CYTOTOXICITY AND GENOTOXICOLOGICAL SAFETY PROFILE OF BIOACTIVE SILVER(I) COMPLEXES WITH AMINOADAMANTANE LIGANDS},

author = {Igor Henrique Cerqueira and Maria Julia Mieli and Anna Karla Pereira and Pedro Paulo Corbi and Flavia Resende},

doi = {10.21577/0100-4042.20240002},

issn = {1678-7064},

year  = {2024},

date = {2024-00-00},

urldate = {2024-00-00},

journal = {Quim. Nova},

publisher = {Sociedade Brasileira de Quimica (SBQ)},

abstract = {<jats:p>Silver(I) complexes of amantadine (atdH), memantine (mtnH) and rimantadine (rtdH), named Ag-atd, Ag-mtn and Ag-rtd, respectively, were recently synthesized and described in the literature as promising antibacterial agents. In the present study, the cytotoxicity of such complexes was evaluated against cultures of primary epidermal keratinocytes (HaCaT) and murine melanoma tumor cells (B16-F10), and mutagenicity was studied by the Ames test to investigate their abilities to induce gene mutations. The Ames test was performed using Salmonella Typhimurium strains (TA98, TA100, TA102 and TA97a) capable of detecting frameshift and base pair substitution gene mutations, in experiments with and without metabolic activation (microsomal fraction S9). This study revealed significant cytotoxic activity against tumor cells and selectivity of Ag-atd and Ag-rtd complexes when compared to non-tumor human keratinocyte cells. Moreover, the Ag(I) complexes did not induce a significant growth in the number of revertant colonies when comparing with the negative control, both in the experiments without and with metabolic activation, indicating absence of mutagenic activity. The results are encouraging and collaborate in the genotoxicological investigations necessary for understanding the interaction and ability of the silver complexes to induce mutations and contribute to ensure their uses as future antibacterial or antitumor agents.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Nakahata2024,

title = {Synthesis, Characterization and in vitro Evaluation of 4-(2-Aminoethyl)benzenesulfonamide Schiff Bases against Arboviruses},

author = {Douglas Nakahata and Carlos Corsino and Guilherme de Morais and Gabriele Pereira and Állefe Cruz and Douglas Henrique Pereira and Natasha Cassani and Uriel Enrique Ruiz and Igor Santos and Ana Carolina Jardim and Pedro Corbi},

doi = {10.21577/0103-5053.20240049},

issn = {1678-4790},

year  = {2024},

date = {2024-00-00},

urldate = {2024-00-00},

journal = {J. Braz. Chem. Soc.},

publisher = {Sociedade Brasileira de Quimica (SBQ)},

abstract = {<jats:p>This study presents the synthesis and characterization of five Schiff bases derived from the reaction of 4-(2-aminoethyl)-benzenesulfonamide (compound 1) with corresponding aldehydes, (benzaldehyde, 2-pyridinecarboxaldehyde, 2-quinolinecarboxaldehyde, 8-hydroxy2-quinolinecarboxaldehyde and 4-imidazolecarboxaldehyde, for compounds 2-6, respectively). Characterization was performed by various spectroscopic techniques and supported by density functional theory (DFT) calculations. The crystal structures revealed how the substituent groups influenced the present supramolecular interactions. Compounds 1-4 and 6 showed no cytotoxicity to BHK-21 and VERO E6 cells at the highest concentration of 50 µmol L-1, while compound 5 was cytotoxic at this concentration. Compound 5 was active against the Chikungunya virus at the concentration of 10 µmol L-1, highlighting the effect of the 8-hydroxyquinoline substituent for the antiviral activity. For Zika virus, compound 6 was the only one active at 50 µmol L-1. The results suggest the potential of combining sulfonamides with other chemotypes for further development of antiviral agents, especially in the treatment of arboviral diseases.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{BormioNunes2023,

title = {Beyond silver sulfadiazine: A dive into more than 50 years of research and development on metal complexes of sulfonamides in medicinal inorganic chemistry},

author = {Julia Helena Bormio Nunes and Douglas Hideki Nakahata and Pedro Paulo Corbi and Raphael Enoque Ferraz de Paiva},

doi = {10.1016/j.ccr.2023.215228},

issn = {0010-8545},

year  = {2023},

date = {2023-09-00},

urldate = {2023-09-00},

journal = {Coordination Chemistry Reviews},

volume = {490},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Silva2023,

title = {Copper(II) and Platinum(II) Naproxenates: Insights on Synthesis, Characterization and Evaluation of Their Antiproliferative Activities},

author = {Amanda A. Silva and Silmara C. L. Frajácomo and Állefe B. Cruz and Kaio Eduardo Buglio and Daniele Daiane Affonso and Marcelo Cecconi Portes and Ana Lúcia T. G. Ruiz and João Ernesto de Carvalho and Wilton R. Lustri and Douglas H. Pereira and Ana M. da Costa Ferreira and Pedro P. Corbi},

doi = {10.3390/inorganics11080331},

issn = {2304-6740},

year  = {2023},

date = {2023-08-00},

urldate = {2023-08-00},

journal = {Inorganics},

volume = {11},

number = {8},

publisher = {MDPI AG},

abstract = {<jats:p>The growth of antibiotic resistance is a matter of worldwide concern. In parallel, cancer remains one of the main causes of death. In the search for new and improved antiproliferative agents, one of the strategies is the combination of bioactive ligands and metals that are already consolidated in the synthesis of metallopharmaceutical agents. Thus, this work deals with the synthesis, characterization, and study of naproxen (Nap)-based complexes of copper(II) and platinum(II) as antiproliferative agents. The copper complex (Cu–Nap) presents a binuclear paddle-wheel structure in a 1 Cu:2 Nap:1 H2O molar composition, in which Cu(II) is bonded to the carboxylate oxygens from naproxenate in a bidentate bridging mode. The platinum complex (Pt–Nap) was identified as the square planar cis-[Pt(Nap)2(DMSO)2] isomer, in which Pt(II) is bonded to the carboxylate oxygen atom of Nap in a monodentate fashion. Both complexes were inactive against the Gram-positive and Gram-negative bacterial strains assessed. Pt–Nap presented low cytostatic behavior over a set of tumor cells, but good viability for normal cells, while Cu–Nap was cytotoxic against all cells, with a cytocidal activity against glioma tumor cells.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Leitao2023,

title = {Gallium and indium complexes with isoniazid-derived ligands: Interaction with biomolecules and biological activity against cancer cells and Mycobacterium tuberculosis},

author = {Renan C.F. Leitao and Francisco Silva and Gabriel H. Ribeiro and Isabel C. Santos and Joana F. Guerreiro and Filipa Mendes and Alzir A. Batista and Fernando R. Pavan and Pedro Ivo da S. Maia and António Paulo and Victor M. Deflon},

doi = {10.1016/j.jinorgbio.2022.112091},

issn = {0162-0134},

year  = {2023},

date = {2023-03-00},

urldate = {2023-03-00},

journal = {Journal of Inorganic Biochemistry},

volume = {240},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid39366100,

title = {Antibacterial profile and antiproliferative activities over human tumor cells of new silver(I) complexes containing two distinct trifluoromethyl uracil isomers},

author = {Gabriele de Menezes Pereira and Julia H Bormio Nunes and Vinicius Souza Macedo and Douglas Henrique Pereira and Kaio Eduardo Buglio and Daniele D Affonso and Ana Lucia T G Ruiz and João Ernesto de Carvalho and Silmara Cristina L Frajácomo and Wilton R Lustri and Carmen Silvia Passos Lima and Fernando R G Bergamini and Alexandre Cuin and Norberto Masciocchi and Pedro Paulo Corbi},

doi = {10.1016/j.jinorgbio.2024.112752},

issn = {1873-3344},

year  = {2024},

date = {2024-10-01},

urldate = {2024-10-01},

journal = {J Inorg Biochem},

volume = {262},

pages = {112752},

abstract = {New silver(I) complexes of 5-(trifluoromethyl)uracil (5TFMU) and 6-(trifluoromethyl)uracil (6TFMU) isomers were synthesized, characterized, and evaluated as antibacterial and antiproliferative agents. Based on elemental and thermogravimetric analyses, the Ag-5TFMU and Ag-6TFMU species are formulated as AgCHFNO and AgCHFNO, respectively. Infrared and C solid-state nuclear magnetic resonance spectroscopies suggest coordination of the trifluoromethyluracil isomers to silver by both nitrogen and oxygen atoms. Confirmation of their structure and connectivity was achieved, in the absence of single crystals of suitable quality, by state-of-the-art structural powder diffraction methods. In Ag-5TFMU, the organic ligand is tridentate and two distinct metal coordination environments are found (linear AgN as well as C AgO geometries), whereas Ag-6TFMU contains a complex polymeric structure with tetradentate dianionic 6TFMU moieties and five distinct AgX (X = N, O) fragments, further stabilized by ancillary (longer) AgO contacts. These species presented modest activity over Gram-positive and Gram-negative bacterial strains, whereas Ag-6TFMU was active over a set of tumor cells, with the best activity over prostate (PC-3) and kidney cell lines and selectivity indices of 4.6 and 1.3, respectively. On the other hand, Ag-5TFMU was active over all considered tumor cells except MCF-7 (breast cancer). The best activity was found for PC-3 cells, but no selectivity was observed. The Ag-5TFMU and Ag-6TFMU species also reduced the proliferation of tongue squamous cell carcinoma cell lines SCC - 4 and SCC-15. Preliminary biophysical assays by circular dichroism suggest that the Ag-5TFMU complex interacts with DNA by intercalation, an effect not seen in Ag-6TFMU.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Mendonça2024,

title = {ASSESSMENT OF IN VITRO INTERACTIONS BETWEEN RADIOLABELED EGFR-TARGETING PEPTIDE INHIBITORS AND GLIOBLASTOMA CELLS},

author = {Fernanda Ferreira Mendonça and Alice Santos de Miranda and Henrique Massao Achidate Makino and Lorena Marinelli Mendes and Danielle Vieira Sobral and Marycel Figols de Barboza and Luciana Malavolta and Leonardo Lima Fuscaldi},

doi = {10.1016/j.htct.2024.04.065},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

pages = {S10--S11},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Rodrigues2024,

title = {ASSESSMENT OF IN VITRO STUDIES OF [131I]I-LABELED DEDEYFELV PEPTIDE AS PROSPECTIVE BIOMARKER FOR GLIOBLASTOMA},

author = {Fernanda Paiva Augusto Rodrigues and Júlia Calviello Giordano and Danielle Vieira Sobral and Ana Cláudia Camargo Miranda and Leonardo Lima Fuscaldi and Marycel Figols de Barboza and João Luiz Vitorino Araújo and Luciana Malavolta},

doi = {10.1016/j.htct.2024.04.063},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

pages = {S9--S10},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Affonso2024,

title = {EVALUATION IN VITRO OF THE GOLD(I) COMPLEX WITH TRIPHENYLPHOSPHINE AND 4-DIMETHYLAAMINEPYRIDINE AS LIGANDS IN SKIN CANCER},

author = {Daniele Daiane Affonso and Tuany Zambroti Candido and João Ernesto de Carvalho and Pedro Paulo Corbi and Camilla Abbehausen and Ana Lucia Tasca Gois Ruiz and Carmen Silvia Passos Lima},

doi = {10.1016/j.htct.2024.04.083},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

pages = {S21--S22},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Mendes2024,

title = {EVALUATION OF POTENTIAL PEPTIDE INHIBITORS THAT INTERACT WITH THE EGF RECEPTOR. RELEVANCE TO GLIOBLASTOMA},

author = {Lorena Marinelli Mendes and Danielle Vieira Sobral and Érica Victória dos Santos and Leonardo Lima Fuscaldi and Luciana Malavolta},

doi = {10.1016/j.htct.2024.04.061},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Mendonça2024b,

title = {INVESTIGATION OF THE IN VITRO ASSESSMENT OF 99MTC-LABELED LAMININ-111 PEPTIDES AS PROSPECTIVE BIOMARKERS FOR BREAST CANCER},

author = {Fernanda Ferreira Mendonça and Maria Emilia Tejeria Perez and Paula Decuadra and Maia Zeni and Ana Rey and Leonardo Lima Fuscaldi and Luciana Malavolta},

doi = {10.1016/j.htct.2024.04.062},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

pages = {S8--S9},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Carron2024,

title = {INFLUENCE OF A CONVENTIONAL CHELATOR-MODIFIED ANTI-INTEGRIN PEPTIDE ON PROLIFERATION AND MIGRATION OF HEAD AND NECK CANCER CELLS},

author = {Juliana Carron and Daniele Daiane Affonso and Suelen Aparecida Ribeiro Souza and Ana Maria Castro Ferreira and João Ernesto Carvalho and Ana Lucia Tasca Gois Ruiz and Gabriella Fraiji Melo and Flávio Lopes Alves and Leonardo Lima Fuscaldi and Luciana Malavolta and Carmen Silvia Passos Lima},

doi = {10.1016/j.htct.2024.04.081},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Lima2024,

title = {PRELIMINARY ANTI-PROLIFERATIVE ACTIVITIES OF A PALLADIUM(II) COMPLEX OVER SQUAMOUS CELL CARCINOMA OF TONGUE},

author = {Carmen Silvia Passos Lima and Tuany Zambroti Candido and João Ernesto de Carvalho and Ana Lucia Tasca Gois Ruiz and Pedro Paulo Corbi},

doi = {10.1016/j.htct.2024.04.075},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

pages = {S16--S17},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Mendonça2024c,

title = {SYNTHESIS AND EVALUATION OF BIOACTIVE PEPTIDES FROM LAMININ-111 IN TRIPLE-NEGATIVE BREAST CANCER CELLS},

author = {Fernanda Ferreira Mendonça and Júlia Torquato Vieira and Danielle Vieira Sobral and Érica Victória dos Santos and Leonardo Lima Fuscaldi and Luciana Malavolta},

doi = {10.1016/j.htct.2024.04.064},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Fuscaldi2023,

title = {Radiochemical and biological assessments of a PSMA-I&S cold kit for fast and inexpensive 99mTc-labeling for SPECT imaging and radioguided surgery in prostate cancer},

author = {Leonardo Lima Fuscaldi and Danielle Vieira Sobral and Ana Claudia Ranucci Durante and Fernanda Ferreira Mendonça and Ana Cláudia Camargo Miranda and Carla Salgueiro and Silvia Gomez de Castiglia and Lilian Yuri Itaya Yamaga and Marcelo Livorsi da Cunha and Luciana Malavolta and Marycel Figols de Barboza and Jorge Mejia},

doi = {10.3389/fchem.2023.1271176},

issn = {2296-2646},

year  = {2023},

date = {2023-10-12},

urldate = {2023-10-12},

journal = {Front. Chem.},

volume = {11},

publisher = {Frontiers Media SA},

abstract = {<jats:p>The expression of prostate-specific membrane antigen (PSMA) is upregulated in prostate cancer (PCa) cells and PSMA-ligands have been radiolabeled and used as radiopharmaceuticals for targeted radionuclide therapy (TRT), single photon emission computed tomography (SPECT) or positron emission tomography (PET) molecular imaging, and radioguided surgery in PCa patients. Herein, we aimed at radiolabeling the PSMA-I&S cold kit with <jats:sup>99m</jats:sup>Tc, resulting in a radiopharmaceutical with high radiochemical yield (RCY) and stability for SPECT imaging and radioguided surgery in PCa malignancies. Various pre-clinical assays were conducted to evaluate the [<jats:sup>99m</jats:sup>Tc]Tc-PSMA-I&S obtained by the cold kit. These assays included assessments of RCY, radiochemical stability in saline, lipophilicity, serum protein binding (SPB), affinity for LNCaP-PCa cells (binding and internalization studies), and <jats:italic>ex vivo</jats:italic> biodistribution profile in naive and LNCaP-PCa-bearing mice. The radiopharmaceutical was obtained with good RCY (92.05% ± 2.20%) and remained stable for 6 h. The lipophilicity was determined to be −2.41 ± 0.06, while the SPB was ∼97%. The binding percentages to LNCaP cells were 9.41% ± 0.57% (1 h) and 10.45% ± 0.45% (4 h), with 63.12 ± 0.93 (1 h) and 65.72% ± 1.28% (4 h) of the bound material being internalized. Blocking assays, employing an excess of unlabeled PSMA-I&S, resulted in a reduction in the binding percentage by 2.6 times. The <jats:italic>ex vivo</jats:italic> biodistribution profile confirmed high accumulation of [<jats:sup>99m</jats:sup>Tc]Tc-PSMA-I&S in the tumor and the tumor-to-contralateral muscle ratio was ∼6.5. In conclusion, [<jats:sup>99m</jats:sup>Tc]Tc-PSMA-I&S was successfully obtained by radiolabeling the cold kit using freshly eluted [<jats:sup>99m</jats:sup>Tc]NaTcO<jats:sub>4</jats:sub>, exhibiting good RCY and radiochemical stability. The preclinical assays demonstrated that the radiopharmaceutical shows favorable characteristics for SPECT imaging and radioguided surgery in PCa patients.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Bergamini2022,

title = {Investigating the antiproliferative activities of new CuII complexes with pyridine hydrazone derivatives of nalidixic acid},

author = {Fernando R.G. Bergamini and Julia H.B. Nunes and Carlos Marrote Manzano and Marcos Alberto de Carvalho and Marcos Antônio Ribeiro and Ana Lucia Tasca Gois Ruiz and João Ernesto de Carvalho and Wilton Rogério Lustri and Raphael Enoque Ferraz de Paiva and Marcelo Cecconi Portes and Ana Maria da Costa Ferreira and Pedro Paulo Corbi},

doi = {10.1016/j.jinorgbio.2022.111881},

issn = {0162-0134},

year  = {2022},

date = {2022-09-00},

urldate = {2022-09-00},

journal = {Journal of Inorganic Biochemistry},

volume = {234},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Candido2022,

title = {Silver Nimesulide Complex in Bacterial Cellulose Membranes as an Innovative Therapeutic Method for Topical Treatment of Skin Squamous Cell Carcinoma},

author = {Tuany Zambroti Candido and Raphael Enoque Ferraz de Paiva and Mariana Cecchetto Figueiredo and Lilian de Oliveira Coser and Silmara Cristina Lazarini Frajácomo and Camilla Abbehausen and Izilda Aparecida Cardinalli and Wilton Rogerio Lustri and João Ernesto Carvalho and Ana Lucia Tasca Gois Ruiz and Pedro Paulo Corbi and Carmen Silvia Passos Lima},

doi = {10.3390/pharmaceutics14020462},

issn = {1999-4923},

year  = {2022},

date = {2022-02-00},

urldate = {2022-02-00},

journal = {Pharmaceutics},

volume = {14},

number = {2},

publisher = {MDPI AG},

abstract = {<jats:p>Oxidative stress and inflammation act on skin squamous cell carcinoma (SSCC) development and progression. Curative therapy for SSCC patients is mainly based on surgical resection, which can cause various sequelae. Silver ions have in vitro activities over tumor cells, while nimesulide has antioxidant and anti-inflammatory activities. This study aimed to evaluate the effects of a silver(I) complex with nimesulide (AgNMS) incorporated in a sustained release device based on bacterial cellulose membrane, named AgNMS@BCM, on topic SSCC treatment. The antiproliferative effect of AgNMS complex was evaluated in the SCC4, SCC15 and FaDu SCC lines. AgNMS complex activity on exposure of phosphatidylserine (PS) residues and multicaspase activation were evaluated on FaDu cells by flow cytometry. The AgNMS@BCM effects were evaluated in a SSCC model induced by 7,12-dimethylbenzanthracene/12-o-tetradecanoyl-phorbol-13-acetate (DMBA/TPA) in mice. Toxicity and tumor size were evaluated throughout the study. AgNMS complex showed antiproliferative activity in SCC15 and FaDu lines in low to moderate concentrations (67.3 µM and 107.3 µM, respectively), and induced multicaspase activation on FaDu cells. The AgNMS@BCM did not induce toxicity and reduced tumor size up to 100%. Thus, the application of AgNMS@BCM was effective and safe in SSCC treatment in mice, and can be seen as a potential and safe agent for topic treatment of SSCC in humans.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Sobral2022,

title = {Comparative Evaluation of Radiochemical and Biological Properties of 131I- and [99mTc]Tc(CO)3-Labeled RGD Analogues Planned to Interact with the αvβ3 Integrin Expressed in Glioblastoma},

author = {Danielle V. Sobral and Leonardo L. Fuscaldi and Ana Claudia R. Durante and Fernanda F. Mendonça and Larissa R. de Oliveira and Ana Cláudia C. Miranda and Jorge Mejia and Wagner R. Montor and Marycel F. de Barboza and Luciana Malavolta},

doi = {10.3390/ph15020116},

issn = {1424-8247},

year  = {2022},

date = {2022-02-00},

urldate = {2022-02-00},

journal = {Pharmaceuticals},

volume = {15},

number = {2},

publisher = {MDPI AG},

abstract = {<jats:p>Radiolabeled peptides with high specificity for overexpressed receptors in tumor cells hold great promise for diagnostic and therapeutic applications. In this work, we aimed at comparing the radiolabeling efficiency and biological properties of two different RGD analogs: GRGDYV and GRGDHV, labeled with iodine-131 (131I) and technetium-99m-tricarbonyl complex [99mTc][Tc(CO)3]+. Additionally, we evaluated their interaction with the αvβ3 integrin molecule, overexpressed in a wide variety of tumors, including glioblastoma. Both peptides were chemically synthesized, purified and radiolabeled with 131I and [99mTc][Tc(CO)3]+ using the chloramine-T and tricarbonyl methodologies, respectively. The stability, binding to serum proteins and partition coefficient were evaluated for both radioconjugates. In addition, the binding and internalization of radiopeptides to rat C6 glioblastoma cells and rat brain homogenates from normal animals and a glioblastoma-induced model were assessed. Finally, ex vivo biodistribution studies were carried out. Radiochemical yields between 95–98% were reached for both peptides under optimized radiolabeling conditions. Both peptides were stable for up to 24 h in saline solution and in human serum. In addition, the radiopeptides have hydrophilic characteristics and a percentage of binding to serum proteins around 35% and 50% for the [131I]I-GRGDYV and [99mTc]Tc(CO)3-GRGDHV fragments, respectively. Radiopeptides showed the capacity of binding and internalization both in cell culture (C6) and rat brain homogenates. Biodistribution studies corroborated the results obtained with brain homogenates and confirmed the different binding characteristics due to the exchange of radionuclides and the presence of the tricarbonyl complex. Thereby, the results showed that both radiopeptides might be considered for future clinical applications.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Fuscaldi2021,

title = {Standardization of the [68Ga]Ga-PSMA-11 Radiolabeling Protocol in an Automatic Synthesis Module: Assessments for PET Imaging of Prostate Cancer},

author = {Leonardo L. Fuscaldi and Danielle V. Sobral and Ana Claudia R. Durante and Fernanda F. Mendonça and Ana Cláudia C. Miranda and Marcelo L. da Cunha and Luciana Malavolta and Jorge Mejia and Marycel F. de Barboza},

doi = {10.3390/ph14050385},

issn = {1424-8247},

year  = {2021},

date = {2021-05-00},

urldate = {2021-05-00},

journal = {Pharmaceuticals},

volume = {14},

number = {5},

publisher = {MDPI AG},

abstract = {<jats:p>Prostate-specific membrane antigen (PSMA) is a glycoprotein present in the prostate, that is overexpressed in prostate cancer (PCa). Recently, PSMA-directed radiopharmaceuticals have been developed, allowing the pinpointing of tumors with the Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) imaging techniques. The aim of the present work was to standardize and validate an automatic synthesis module-based radiolabeling protocol for [68Ga]Ga-PSMA-11, as well as to produce a radiopharmaceutical for PET imaging of PCa malignancies. [68Ga]Ga-PSMA-11 was evaluated to determine the radiochemical purity (RCP), stability in saline solution and serum, lipophilicity, affinity to serum proteins, binding and internalization to lymph node carcinoma of the prostate (LNCaP) cells, and ex vivo biodistribution in mice. The radiopharmaceutical was produced with an RCP of 99.06 ± 0.10%, which was assessed with reversed-phase high-performance liquid chromatography (RP-HPLC). The product was stable in saline solution for up to 4 h (RCP > 98%) and in serum for up to 1 h (RCP > 95%). The lipophilicity was determined as −3.80 ± 0.15, while the serum protein binding (SPB) was <17%. The percentages of binding to LNCaP cells were 4.07 ± 0.51% (30 min) and 4.56 ± 0.46% (60 min), while 19.22 ± 2.73% (30 min) and 16.85 ± 1.34% (60 min) of bound material was internalized. High accumulation of [68Ga]Ga-PSMA-11 was observed in the kidneys, spleen, and tumor, with a tumor-to-contralateral-muscle ratio of >8.5 and a tumor-to-blood ratio of >3.5. In conclusion, an automatic synthesis module-based radiolabeling protocol for [68Ga]Ga-PSMA-11 was standardized and the product was evaluated, thus verifying its characteristics for PET imaging of PCa tumors in a clinical environment.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Sobral2020,

title = {Radiochemical and biological properties of peptides designed to interact with EGF receptor: Relevance for glioblastoma},

author = {Danielle V. Sobral and Leonardo L. Fuscaldi and Ana Claudia R. Durante and Mayara G. Rangel and Larissa R. Oliveira and Fernanda F. Mendonça and Ana Cláudia C. Miranda and Jorge M. Cabeza and Wagner R. Montor and Francisco R. Cabral and Marycel F.F. Barboza and Luciana Malavolta},

doi = {10.1016/j.nucmedbio.2020.07.001},

issn = {0969-8051},

year  = {2020},

date = {2020-09-00},

urldate = {2020-09-00},

journal = {Nuclear Medicine and Biology},

volume = {88-89},

pages = {14--23},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{BormioNunes2019,

title = {New findings on the antiproliferative activity of the silver(I) complex with 5-fluorouracil against human multi-resistant NCI/ADR-RES ovarian tumor cells},

author = {Julia H. Bormio Nunes and Paula P. de Paiva and Ana Lúcia T.G. Ruiz and João Ernesto de Carvalho and Pedro P. Corbi},

doi = {10.1016/j.tiv.2019.06.018},

issn = {0887-2333},

year  = {2019},

date = {2019-10-00},

urldate = {2019-10-00},

journal = {Toxicology in Vitro},

volume = {60},

pages = {359--368},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Souza2025,

title = {Brazilian profile of Radium-223 in metastatic prostate cancer: a multicentric, retrospective study},

author = {Stephan Souza and Felipe Ribeiro and Ana Brito and Thaís Minekawa and Flávia Lopes and Sumara Matedi and Renata Fockink and Dalton Anjos and Gustavo Gomes and Laura Silva and Mariana Camacho and Allan Santos and Whemberton Araújo and Ana Teixeira and Raul Martins and Adelina Sanches and Nilton Hanaoka and Rafael Tavares and Felipe Villela-Pedras and Felipe Mourato and Caroline Torricelli and Thiago Alves and Marcelo Tavares and Mariana Lima and André Moraes and André Sasse and Paulo Almeida and Elba Etchebehere},

doi = {10.1186/s41824-025-00245-9},

issn = {3005-074X},

year  = {2025},

date = {2025-12-00},

urldate = {2025-12-00},

journal = {EJNMMI Rep.},

volume = {9},

number = {1},

publisher = {Springer Science and Business Media LLC},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Carrilho2025b,

title = {Prognostic impact of low muscularity in metastatic and recurrent head and neck cancer: Insights from C3-based assessments},

author = {Larissa Ariel Oliveira Carrilho and Livia Dias Guerra and Rafaella Caroline de Lellis Moreira and Fabiana Lascala Juliani and Fernanda Silva Santos and Daniela Morais de Holanda Padilha and Fabíola Furtuoso Zaperlão and Sandra Regina Branbilla and Vivian Naomi Horita and Davi Magalhães Leite Novaes and Lígia Moraes Antunes-Correa and Carmem Silvia Passos Lima and Maria Carolina Santos Mendes and José Barreto Campello Carvalheira},

doi = {10.1016/j.clnesp.2025.06.029},

issn = {2405-4577},

year  = {2025},

date = {2025-08-00},

urldate = {2025-08-00},

journal = {Clinical Nutrition ESPEN},

volume = {68},

pages = {767--773},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Carrilho2025,

title = {Adipose tissue characteristics as a new prognosis marker of patients with locally advanced head and neck cancer},

author = {Larissa Ariel Oliveira Carrilho and Fabiana Lascala Juliani and Rafaella Caroline de Lellis Moreira and Livia Dias Guerra and Fernanda Silva Santos and Daniela Morais de Holanda Padilha and Sandra Regina Branbilla and Vivian Naomi Horita and Davi Magalhães Leite Novaes and Lígia Macedo Antunes-Correa and Carmem Silvia Passos Lima and Maria Carolina Santos Mendes and José Barreto Campello Carvalheira},

doi = {10.3389/fnut.2025.1472634},

issn = {2296-861X},

year  = {2025},

date = {2025-03-14},

urldate = {2025-03-14},

journal = {Front. Nutr.},

volume = {12},

publisher = {Frontiers Media SA},

abstract = {<jats:sec><jats:title>Background</jats:title><jats:p>Patients with head and neck cancer (HNC) are at increased risk of malnutrition due to the presence of tumor and treatments. Body composition is a prognostic factor in these patients. However, the relationship between adipose tissue characteristics and survival in HNC is still unclear.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>To evaluate the associations of adiposity, the radiodensity of adipose tissue and muscularity with the prognosis of patients with locally advanced HNC undergoing to chemoradiotherapy.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This retrospective study included 132 patients diagnosed with locally advanced HNC. Body composition assessment was performed using computed tomography (CT) images at the level of the third cervical vertebra (C3). The total adipose tissue radiodensity (TATR), the total adipose tissue index (TATI) and skeletal muscle index (SMI) were evaluated. The primary outcome was overall survival (OS).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Patients in the highest TATI tertile had a lower risk of mortality when compared to those in the lowest tertile, HR: 0.56, 95% confidence Interval (CI): 0.32–0.96; <jats:italic>p</jats:italic> = 0.039. The highest TATR tertile was not associated with death. Patients with greater adiposity had a higher median survival compared to patients with medium and lower TATI (<jats:italic>p</jats:italic> = 0.0193). Individuals with lower TATI had lower energy intake than patients with higher TATI (<jats:italic>p</jats:italic> = 0.03). Additionally, patients with low muscularity had worse OS in the multivariable analysis (HR: 1.77, 95% CI: 1.01–3.07; <jats:italic>p</jats:italic> = 0.044).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>In patients with locally advanced HNC, our findings underscore the significance of elevated adiposity, beyond maintained muscularity, as independent protective factors for overall survival. Our study highlights the critical importance of assessing body composition and initiating early nutritional interventions to improve the prognosis of these patients.</jats:p></jats:sec>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{deMenezesPereira2025,

title = {Antibacterial profile and antiproliferative activities over human tumor cells of new silver(I) complexes containing two distinct trifluoromethyl uracil isomers},

author = {Gabriele de Menezes Pereira and Julia H. Bormio Nunes and Vinicius Souza Macedo and Douglas Henrique Pereira and Kaio Eduardo Buglio and Daniele D. Affonso and Ana Lucia T.G. Ruiz and João Ernesto de Carvalho and Silmara Cristina L. Frajácomo and Wilton R. Lustri and Carmen Silvia Passos Lima and Fernando R.G. Bergamini and Alexandre Cuin and Norberto Masciocchi and Pedro Paulo Corbi},

doi = {10.1016/j.jinorgbio.2024.112752},

issn = {0162-0134},

year  = {2025},

date = {2025-01-00},

urldate = {2025-01-00},

journal = {Journal of Inorganic Biochemistry},

volume = {262},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Genaro2025,

title = {Therapeutic drug monitoring and immunogenetic factors associated with the use of adalimumab in Crohn’s disease patients},

author = {Livia Moreira Genaro and Juliana Carron and Marina Moreira de Castro and Ana Paula Menezes de Freitas Franceschini and Gustavo Jacob Lourenço and Cristiane Kibune Nagasako Vieira da Cruz and Glaucia Fernanda Soares Rupert Reis and Livia Bitencourt Pascoal and Juliana Delgado Campos Mello and Isabela Machado Pereira and Millene Leal Nascimento and Priscilla De Sene Portel Oliveira and Ligiana Pires Corona and Maria de Lourdes Setsuko Ayrizono and Carmen Silvia Passos Lima and Raquel Franco Leal},

doi = {10.1177/03946320251319379},

issn = {2058-7384},

year  = {2025},

date = {2025-01-00},

urldate = {2025-01-00},

journal = {Int J Immunopathol Pharmacol},

volume = {39},

publisher = {SAGE Publications},

abstract = {<jats:p> Crohn’s disease (CD) involves immune system interactions with intestinal tissue, driven by pro-inflammatory cytokines like Tumor Necrosis Factor (TNF-α). Adalimumab, targeting TNF-α, regulates associated inflammatory responses. Despite being humanized, it may induce immunogenic processes, affecting treatment effectiveness. Thus, monitoring serum adalimumab and anti-drug antibody (ADA) levels can optimize therapy. Understanding genetic factors influencing adalimumab response can enhance personalized treatment and improve patient quality of life. We aimed to quantify adalimumab serum levels, assess test interchangeability, detect ADA, examine immune complex formation, and investigate genetic phenotypes related to immunogenicity in CD patients. Seventy CD patients in the maintenance phase with adalimumab were classified into active (CDA) and remission (CDR) groups. Adalimumab concentration was determined via enzyme-linked immunosorbent assay (ELISA—Promonitor) and lateral flow assay (Quantum Blue), with assay interchangeability assessed statistically. ADA and immune complex formation were quantified using ELISA assays. DNA was genotyped for the genes ATG16L1, CD96, and CD155. No significant differences in adalimumab serum concentrations were observed between groups, regardless of the assay. However, a statistical difference between the tests indicated measurement disparity ( P = 0.003), with moderate agreement (Lin’s correlation of 0.247). ADA was detected in 4 of 27 of the patients with infratherapeutic levels, 3 in the CDA group and 1 in the CDR group. Analysis of immune complexes revealed significantly higher concentrations in the CDA group ( P = 0.0125). The genotypic evaluation revealed significant associations for the CD96 CC (wild-type) genotype with higher CRP levels, colonic involvement, and infratherapeutic levels of adalimumab. ATG16L1 CC genotype was associated with higher CDEIS and fecal calprotectin values, while the variant (TT) genotype had lower platelet counts. The effectiveness of treatment with adalimumab was not directly related to higher medication levels in this cohort. The disparity between tests indicates the need to use only one test in patient follow-up to ensure accuracy in therapeutic monitoring. Genotypic differences highlight the correlation between the wild genotype for CD96 and ATG16L1 with unfavorable laboratory and endoscopic response to adalimumab. Finally, the more significant levels of immune complexes in the CDA group indicate an association with a worse response to adalimumab. </jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Liveraro2025,

title = {Improving resectable gastric cancer prognosis prediction: A machine learning analysis combining clinical features and body composition radiomics},

author = {Gianni S.S. Liveraro and Maria E.S. Takahashi and Fabiana Lascala and Luiz R. Lopes and Nelson A. Andreollo and Maria C.S. Mendes and Jun Takahashi and José B.C. Carvalheira},

doi = {10.1016/j.imu.2024.101608},

issn = {2352-9148},

year  = {2025},

date = {2025-00-00},

urldate = {2025-00-00},

journal = {Informatics in Medicine Unlocked},

volume = {52},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Padilha2024,

title = {Subcutaneous adipose tissue radiodensity: An emerging risk factor for severe COVID-19},

author = {Daniela M.H. Padilha and Maria C.S. Mendes and Maria E.S. Takahashi and Fabiana Lascala and Marina N. Silveira and Lara Pozzuto and Larissa A.O. Carrilho and Lívia D. Guerra and Rafaella C.L. Moreira and Sandra R. Branbilla and Celso Darío Ramos and José B.C. Carvalheira},

doi = {10.1016/j.nut.2024.112561},

issn = {0899-9007},

year  = {2024},

date = {2024-12-00},

urldate = {2024-12-00},

journal = {Nutrition},

volume = {128},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Carron2024b,

title = {The impact of ERP29 on the progression of pharyngeal squamous cell carcinoma},

author = {Juliana Carron and Lilian de Oliveira Coser and Carmen Silvia Passos Lima and Gustavo Jacob Lourenço},

doi = {10.1038/s41598-024-76210-6},

issn = {2045-2322},

year  = {2024},

date = {2024-12-00},

urldate = {2024-12-00},

journal = {Sci Rep},

volume = {14},

number = {1},

publisher = {Springer Science and Business Media LLC},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Nogueira-Lima2024,

title = {18F-Fluoride PET/CT—Updates},

author = {Ellen Nogueira-Lima and Thiago Alves and Elba Etchebehere},

doi = {10.1053/j.semnuclmed.2024.09.005},

issn = {0001-2998},

year  = {2024},

date = {2024-11-00},

urldate = {2024-11-00},

journal = {Seminars in Nuclear Medicine},

volume = {54},

number = {6},

pages = {951--965},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Silva2024c,

title = {Assessing the role of prognostic nutritional index in predicting outcomes for rectal cancer surgery},

author = {Amanda Cristina Ribeiro Silva and Lígia de Moraes Antunes-Correa and Fabiana Lascala Juliani and Larissa Ariel Oliveira Carrilho and Felipe Osório Costa and Carlos Augusto Real Martinez and Maria Carolina Santos Mendes and José Barreto Campello Carvalheira},

doi = {10.1016/j.clnesp.2024.07.1058},

issn = {2405-4577},

year  = {2024},

date = {2024-10-00},

urldate = {2024-10-00},

journal = {Clinical Nutrition ESPEN},

volume = {63},

pages = {644--650},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Almeida2024,

title = {Radioligand Therapy in Lymphoma},

author = {Ludmila Santiago Almeida and Roberto C. Delgado Bolton and Victor Cabral Heringer and Samuel de Souza Medina and Elba Etchebehere},

doi = {10.1016/j.cpet.2024.05.003},

issn = {1556-8598},

year  = {2024},

date = {2024-07-00},

urldate = {2024-07-00},

journal = {PET Clinics},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Heringer2024,

title = {177LU-PSMA IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER: PRELIMINARY ANALYSIS OF A BRAZILIAN MULTICENTRIC STUDY},

author = {Victor Cabral Costa Ribeiro Heringer and Felipe P.G. Ribeiro and Diogo Bastos and Camila Mosci and Dalton A. Anjos and Paulo Almeida Filho and Gustavo Gomes and Filipe Villela-Pedras and Fabio Ribeiro and Julio Correia and José F. Marin and Carlos Buchpiguel and Elba C.S.C. Etchebehere},

doi = {10.1016/j.htct.2024.04.071},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{doNascimento2024,

title = {18F-FLUORIDE PET/CT vs 18F-PSMA-1007 TO DETECT BONE METASTASES IN PROSTATE CANCER – A HEAD-TO-HEAD PROSPECTIVE COMPARISON},

author = {Beatriz Birelli do Nascimento and Allan Santos and Natalia Tobar and Fabiana Mori and Mariana Camacho and Mariana Lima and Edna Brunetto and Sergio Brunetto and Anelise Ruzzarin and Juliana Ciampi and Marina Silveira and Gardenia Oliveira Barbosa and Wagner Matheus and Ubirajara Ferreira and Elba Etchebehere},

doi = {10.1016/j.htct.2024.04.088},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

pages = {S24--S25},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Heringer2024d,

title = {ARTIFICIAL INTELLIGENCE TO EVALUATE METABOLIC TUMOR BURDEN IN PRIMARY STAGING OF RECTAL CANCER WITH 18F-FDG PET/CT},

author = {Victor Cabral Costa Ribeiro Heringer and Maria Carolina S. Mendes and Barbara Juarez Amorim and Allan Oliveira Santos and Marina N. Silveira and Cleide Silva and Juliano S. Fonseca and Mariana C.L. Lima and Lorena P. Cunha and Carlos Augusto R. Martinez and Claudio Coy and Jose Barreto C. Carvalheira and Elba Cristina Sá de Camargo Etchebehere},

doi = {10.1016/j.htct.2024.04.054},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

pages = {S3--S4},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Silveira2024,

title = {COMPARISON OF 18F-FDG AND 18F-PSMA PET/CT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER},

author = {Najua Abou Arabi Silveira and Maurício Wesley Perroud Júnior and Hugo Nakano Ide and Kaique Moraes do Amaral and Simone Kuba and Natália Tobar and Thiago Ferreira de Souza and Carmen Silva Passos Lima and José Barreto Campello Carvalheira and Barbara Juarez Amorim and Elba Cristina Sá de Camargo Etchebehere and Mariana da Cunha Lopes de Lima and Allan de Oliveira Santos and Ludimila Santiago Almeida and Maria Emília Seren Takahashi and Eliana Cristina Martins Miranda and Carmino Antonio de Souza and Sérgio Querino Brunetto and Celso Dario Ramos},

doi = {10.1016/j.htct.2024.04.079},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Sousa2024,

title = {COMPARISON OF 18 F-FDG AND 18 F-PSMA-1007 PET/CT IN ADVANCED LOCOREGIONAL SQUAMOUS CELL CARCINOMA OF HEAD AND NECK: PRELIMINARY RESULTS},

author = {Hadila Da Silva Veras Sousa and Kaique Moraes do Amaral and Najua Abou Arab and Simone Kuba and Lígia Traldi Macedo and Bárbara Juarez Amorim and Celso Dario Ramos and Carmen Silvia Passos Lima},

doi = {10.1016/j.htct.2024.04.084},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

pages = {S22--S23},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Tineo2024,

title = {COMPARISON BETWEEN PET/CT WITH 18F-PSMA-1007 AND WITH 18F-FDG IN MUSCLE-INVASIVE BLADDER UROTHELIAL CARCINOMA},

author = {Ricardo Norberto Tineo and Natalia Dalsenter Avilez and Juliano Tomé Rodrigues and Felipe Piccarone G Ribeiro and Helena Paes de Alm de Saito and Frederico Leal and Barbara Juazer Amorim and Jose Barrreto C. Carvalheira and Leonardo Oliveira Reis and Celso Dario Ramos},

doi = {10.1016/j.htct.2024.04.086},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

pages = {S23--S24},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Silva2024,

title = {COMPARISON OF PET/CT IMAGES WITH 18F-FDG AND 18F-PSMA-1007 IN MUSCULOSKELETAL TUMORS TO EVALUATE THE POTENTIAL OF THERANOSTICS APPROACH},

author = {Mayara Branco E. Silva and Natalia Tobar and Allan de Oliveira Santos and Gardenia De Oliveira Barbosa and Carlos Eduardo Hideo Hanasilo and Mariana Da Cunha Lopes de Lima and Mauricio Etchebehere and Elba Cristina Sa de Camargo Etchebehere},

doi = {10.1016/j.htct.2024.04.089},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

pages = {S25--S26},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Mendanha2024,

title = {COMPARISON OF PET/CT IMAGES WITH 18F-FDG AND 18F-PSMA-1007 IN METASTATIC ACRAL MELANOMA: A CASE REPORT},

author = {Diego Machado Mendanha and Natalia Tobar and Ligia Traldi Macedo and Allan Oliveira Santos and Mariana Cunha Lopes de Lima and Elba Cristina Sá de Camargo Etchebehere and Carmen Silvia Passos Lima},

doi = {10.1016/j.htct.2024.04.102},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Sousa2024b,

title = {COMPARISON OF PET/CT IMAGES WITH 18 F-FDG AND 18 F-PSMA-1007 IN RELAPSED ADENOID CYSTIC CARCINOMA},

author = {Hadila Da Silva Veras Sousa and Natália Tobar and Lígia Traldi Macedo and Simone Kuba and Allan de Oliveira Santos and Bárbara Juarez Amorim and Carmen Silvia Passos Lima and Elba Cristina Sá de Camargo Etchebehere},

doi = {10.1016/j.htct.2024.04.082},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Takahashi2024,

title = {COMPARISON OF IBI AND PBI CALCULATED FOR 68GA-PSMA AND 18F-FDG IN MULTIPLE MYELOMA PATIENTS},

author = {Maria Emilia Seren Takahashi and Stephan P.M. Souza and Fernanda C. Frasson and Gislaine B. Oliveira and Vania P. Castro and Fernando V. Pericole and Lício A. Velloso and Cármino A. Souza and Irene G.H. Lorand-Metze and Allan O. Santos and Celso Darío Ramos},

doi = {10.1016/j.htct.2024.04.087},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Reis2024,

title = {COMPARISON OF 68GA-PSMA AND 18F-FDG-PET/CT IN THE ASSESSMENT OF DESMOID TUMORS},

author = {Tobias Luis dos Reis and Kaique Moraes do Amaral and Najua Abou Arab and Maria Emilia Seren Takahashi and José Barreto Campello Carvalheira and Barbara Juarez Amorim and Elba Cristina Sá de Camargo Etchebehere and Mariana da Cunha Lopes de Lima and Allan de Oliveira Santos and Ludmila Santiago Almeida and Eliana Cristina Martins Miranda and Carmen Silvia Passos Lima and Celso Dario Ramos and Sérgio Querino Brunetto and Simone Kuba and NAtália Tobar and Carmino Antonio Souza and Mariana Cortês Caleffi and Mariana Fernandes França Mitre Amorim},

doi = {10.1016/j.htct.2024.04.080},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

pages = {S19--S20},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Amaral2024,

title = {DUAL-TRACER PET/CT IN MYELOFIBROSIS: A CASE SERIES ANALYSIS USING 18F-FDG AND 18F-PSMA PET/CT},

author = {Kaique M. Amaral and Katia B.B. Pagnano and Victor Cabral Costa Ribeiro Heringer and Sergio Q. Brunetto and Simone Kuba and Maria Emilia S. Takahashi and Allan O. Santos and Barbara J. Amorim and Elba C.S.C. Etchebehere and Mariana C.L. Lima and Carmino A. Souza and Celso D. Ramos},

doi = {10.1016/j.htct.2024.04.109},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Liveraro2024,

title = {DEEP LEARNING FOR CT IMAGES SEGMENTATION},

author = {Gianni Shigeru Setoue Liveraro and Maria Emília Seren Takahashi and Fabiana Lascala and Maria Carolina Santos Mendes and Jun Takahashi and José Barreto Campello Carvalheira},

doi = {10.1016/j.htct.2024.04.058},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{HERINGER2024b,

title = {RADIOLIGAND THERAPY IN LYMPHOMA: PAST, PRESENT AND FUTURE},

author = {Victor C.C.R. HERINGER and Ludmila S. ALMEIDA and Roberto C. DELGADO BOLTON and Daniel C. PANCIEIRA and Samuel S MEDINA and Elba C.S.C. ETCHEBEHERE},

doi = {10.1016/j.htct.2024.04.115},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Amaral2024b,

title = {TREATMENT OF REFRACTORY MULTIPLE MYELOMA WITH PSMA-177LU: A CASE REPORT},

author = {Kaique M. Amaral and Felipe P.G. Ribeiro and Fernando V.P. Souza and Allan O. Santos and Sergio Q. Brunetto and Maria Emilia S. Takahashi and Vania P. Castro and Carmem S.P. Lima and Barbara J. Amorim and Carmino A. Souza and Celso D. Ramos},

doi = {10.1016/j.htct.2024.04.104},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{ETCHEBEHERE2024,

title = {THERANOSTICS: NUCLEAR MEDICINE IN PROSTATE CANCER},

author = {Marina Camargo ETCHEBEHERE and Helena da Cunha Lopes DE LIMA and Mariana da Cunha Lopes DE LIMA and Elba Cristina Sá de Camargo ETCHEBEHERE},

doi = {10.1016/j.htct.2024.04.111},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Siqueira2024,

title = {TRATAMENTO BEM-SUCEDIDO DE PACIENTE COM DIAGNÓSTICO DE VIPOMA METASTÁTICO COM TRATAMENTO TERANÓSTICO OCTREOTATO-DOTA-177 LUTÉCIO},

author = {Nadia Sclearuc de Siqueira and Helena Paes Almeida Saito and Felipe Osorio Costa and Everton Cazzo and Allan Oliveira Santos and Jose Barreto Campello Carvalheira},

doi = {10.1016/j.htct.2024.04.097},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Heringer2024c,

title = {THE ROLE OF PET/CT IN DETECTING OCCULT DISEASE IN SYNCHRONOUS TUMORS: A CASE REPORT OF MERKEL CELL CARCINOMA AND NON-HODGKIN LYMPHOMA},

author = {Victor C.C.R. Heringer and Fabíola F. Zarpelão and Kaique M. Amaral and Nájua A.A. Silveira and Ricardo N. Tineo and Thais A. Tognoli and Dihego F. Santos and Felipe P.G. Ribeiro and Thiago F. Souza and Mariana Lima and Allan O. Santos and Barbara J. Amorim and Elba C.S.C. Etchebehere and Ludmila S. Almeida and Carmen S.P. Lima and Jose B.C. Carvalheira and Celso D. Ramos},

doi = {10.1016/j.htct.2024.04.100},

issn = {2531-1379},

year  = {2024},

date = {2024-04-00},

urldate = {2024-04-00},

journal = {Hematology, Transfusion and Cell Therapy},

volume = {46},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid38472569,

title = {Evidence of brain metabolism redistribution from neocortex to primitive brain structures in early acute COVID-19 respiratory syndrome},

author = {Stephan P M Souza and Nicoli Colet and Mariana Fujiwara and Alins P Fernandes and Natalia Tobar and Sergio S J Dertkigil and Maria Emilia S Takahashi and Bárbara J Amorim and Lucas S Silva and Clarissa L Yasuda and Fernando Cendes and Thiago F de Souza and Juliano T Rodrigues and Denise E Zantut-Wittmann and Celso Dario Ramos},

doi = {10.1186/s13550-024-01089-3},

issn = {2191-219X},

year  = {2024},

date = {2024-03-01},

urldate = {2024-03-01},

journal = {EJNMMI Res},

volume = {14},

number = {1},

pages = {28},

abstract = {BACKGROUND: Neuropsychiatric sequelae of COVID-19 have been widely documented in patients with severe neurological symptoms during the chronic or subacute phase of the disease. However, it remains unclear whether subclinical changes in brain metabolism can occur early in the acute phase of the disease. The aim of this study was to identify and quantify changes in brain metabolism in patients hospitalized for acute respiratory syndrome due to COVID-19 with no or mild neurological symptoms.nnRESULTS: Twenty-three non-intubated patients (13 women; mean age 55.5 ± 12.1 years) hospitalized with positive nasopharyngeal swab test (RT-PCR) for COVID-19, requiring supplemental oxygen and no or mild neurological symptoms were studied. Serum C-reactive protein measured at admission ranged from 6.43 to 189.0 mg/L (mean: 96.9 ± 54.2 mg/L). The mean supplemental oxygen demand was 2.9 ± 1.4 L/min. [F]FDG PET/CT images were acquired with a median of 12 (4-20) days of symptoms. After visual interpretation of the images, semiquantitative analysis of [F]FDG uptake in multiple brain regions was evaluated using dedicated software and the standard deviation (SD) of brain uptake in each region was automatically calculated in comparison with reference values of a normal database. Evolutionarily ancient structures showed positive SD mean values of [F]FDG uptake. Lenticular nuclei were bilaterally hypermetabolic (> 2 SD) in 21/23 (91.3%) patients, and thalamus in 16/23 (69.6%), bilaterally in 11/23 (47.8%). About half of patients showed hypermetabolism in brainstems, 40% in hippocampi, and 30% in cerebellums. In contrast, neocortical regions (frontal, parietal, temporal and occipital lobes) presented negative SD mean values of [F]FDG uptake and hypometabolism (< 2 SD) was observed in up to a third of patients. Associations were found between hypoxia, inflammation, coagulation markers, and [F]FDG uptake in various brain structures.nnCONCLUSIONS: Brain metabolism is clearly affected during the acute phase of COVID-19 respiratory syndrome in neurologically asymptomatic or oligosymptomatic patients. The most frequent finding is marked hypermetabolism in evolutionary ancient structures such as lenticular nucleus and thalami. Neocortical metabolism was reduced in up to one third of patients, suggesting a redistribution of brain metabolism from the neocortex to evolutionary ancient brain structures in these patients.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Baldissin2023,

title = {FDG–PET in patients with autoimmune encephalitis: a review of findings and new perspectives},

author = {Maurício Martins Baldissin and Edna Marina de Souza and Nancy Watanabe and Elba C. S. C. Etchebehere and Fernando Cendes and Bárbara Juarez Amorim},

doi = {10.1007/s40336-023-00581-5},

issn = {2281-7565},

year  = {2024},

date = {2024-02-00},

urldate = {2024-02-00},

journal = {Clin Transl Imaging},

volume = {12},

number = {1},

pages = {15--30},

publisher = {Springer Science and Business Media LLC},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Almeida2023,

title = {PSMA Radioligand Therapy in Prostate Cancer},

author = {Ludmila Santiago Almeida and Elba Cristina Sá de Camargo Etchebehere and Irene García Megías and Adriana K. Calapaquí Terán and Boris Hadaschik and Patrick M. Colletti and Ken Herrmann and Francesco Giammarile and Roberto C. Delgado Bolton},

doi = {10.1097/rlu.0000000000004919},

issn = {1536-0229},

year  = {2024},

date = {2024-00-00},

urldate = {2024-00-00},

journal = {Clin Nucl Med},

volume = {49},

number = {1},

pages = {45--55},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

abstract = {<jats:title>Abstract</jats:title>

          <jats:p>Diagnosis and treatment of prostate cancer are complex and very challenging, being a major health care burden. The efficacy of radioligand therapy with prostate-specific membrane antigen agents has been proven beneficial in certain clinical indications. In this review, we describe management of prostate cancer patients according to current guidelines, especially focusing on the available clinical evidence for prostate-specific membrane antigen radioligand therapy.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Souza2023,

title = {Head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]FDG PET/CT in multiple myeloma},

author = {Stephan P. M. Souza and Fernanda C. Frasson and Maria Emilia S. Takahashi and Gislaine B. O. Duarte and Vania P. Castro and Fernando V. Pericole and Licio A. Velloso and Carmino A. De Souza and Irene Lorand-Metze and Allan O. Santos and Celso D. Ramos},

doi = {10.1007/s00259-023-06214-3},

issn = {1619-7089},

year  = {2023},

date = {2023-07-00},

urldate = {2023-07-00},

journal = {Eur J Nucl Med Mol Imaging},

volume = {50},

number = {8},

pages = {2432--2440},

publisher = {Springer Science and Business Media LLC},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid36656866,

title = {Metformin acts in the gut and induces gut-liver crosstalk},

author = {Natália Tobar and Guilherme Z Rocha and Andrey Santos and Dioze Guadagnini and Heloísa B Assalin and Juliana A Camargo and Any E S S Gonçalves and Flavia R Pallis and Alexandre G Oliveira and Silvana A Rocco and Raphael M Neto and Irene Layane de Sousa and Marcos R Alborghetti and Maurício L Sforça and Patrícia B Rodrigues and Raissa G Ludwig and Emerielle C Vanzela and Sergio Q Brunetto and Patrícia A Boer and José A R Gontijo and Bruno Geloneze and Carla R O Carvalho and Patricia O Prada and Franco Folli and Rui Curi and Marcelo A Mori and Marco A R Vinolo and Celso D Ramos and Kleber G Franchini and Claudio F Tormena and Mario J A Saad},

doi = {10.1073/pnas.2211933120},

issn = {1091-6490},

year  = {2023},

date = {2023-01-01},

urldate = {2023-01-01},

journal = {Proc Natl Acad Sci U S A},

volume = {120},

number = {4},

pages = {e2211933120},

abstract = {Metformin is the most prescribed drug for DM2, but its site and mechanism of action are still not well established. Here, we investigated the effects of metformin on basolateral intestinal glucose uptake (BIGU), and its consequences on hepatic glucose production (HGP). In diabetic patients and mice, the primary site of metformin action was the gut, increasing BIGU, evaluated through PET-CT. In mice and CaCo2 cells, this increase in BIGU resulted from an increase in GLUT1 and GLUT2, secondary to ATF4 and AMPK. In hyperglycemia, metformin increased the lactate (reducing pH and bicarbonate in portal vein) and acetate production in the gut, modulating liver pyruvate carboxylase, MPC1/2, and FBP1, establishing a gut-liver crosstalk that reduces HGP. In normoglycemia, metformin-induced increases in BIGU is accompanied by hypoglycemia in the portal vein, generating a counter-regulatory mechanism that avoids reductions or even increases HGP. In summary, metformin increases BIGU and through gut-liver crosstalk influences HGP.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Ramos2022,

title = {Beyond the \textit{AJR}: The Rapid Clinical Acceptance of PSMA PET Causes Important Bias in Open-Label Trials},

author = {Celso Dario Ramos},

doi = {10.2214/ajr.21.27241},

issn = {1546-3141},

year  = {2022},

date = {2022-08-00},

urldate = {2022-08-00},

journal = {American Journal of Roentgenology},

volume = {219},

number = {2},

pages = {349--349},

publisher = {American Roentgen Ray Society},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{deSouzaSantos2022,

title = {18F-FDG PET/CT in Late Acquisition Identifies Sites of Active Disease in Treated Takayasu Arteritis},

author = {Marília Paula de Souza Santos and Celso Dario Ramos and Mariana Paixão and Estephania Pignaton Naseri and Manoel Barros Bertolo and Zoraida Sachetto},

doi = {10.1097/rhu.0000000000001801},

issn = {1536-7355},

year  = {2022},

date = {2022-00-00},

urldate = {2022-00-00},

journal = {J Clin Rheumatol},

volume = {28},

number = {1},

pages = {14--20},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

abstract = {<jats:sec>

            <jats:title>Objective</jats:title>

            <jats:p>Few studies have taken advantage of <jats:sup>18</jats:sup>F-fluorodeoxyglucose positron emission tomography associated with computed tomography (<jats:sup>18</jats:sup>F-FDG PET/CT) to personalize patient evaluation and identify sites of more active disease in Takayasu arteritis (TA)–treated patients. This study aimed to evaluate the utility of <jats:sup>18</jats:sup>F-FDG PET/CT in late acquisition in identifying sites of active disease in patients under full treatment for TA.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Methods</jats:title>

            <jats:p>In this cross-sectional study, patients under full treatment underwent whole-body <jats:sup>18</jats:sup>F-FDG PET/CT. Sites of increased <jats:sup>18</jats:sup>F-FDG uptake were classified by a score of 3 on the visual scale using the liver uptake as reference. A quantitative analysis was also performed by measuring the maximum standardized uptake value (SUV) of the vascular wall of affected arteries. Disease activity using the National Institutes of Health criteria was also evaluated.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Results</jats:title>

            <jats:p>Of the 20 patients, there were 18 female and 2 male patients, with a mean age of 43.6 (±11.58) years and a disease duration of 8.3 (±6.25) years. Thirteen participants (65%) were in inflammatory activity according to the criteria proposed by the National Institutes of Health. All patients received immunosuppressive agents, and one of them received immunobiological treatment. The highest SUV value was 6.2 in the aortic arch, and the lowest was 1.0 in the subclavian artery. The mean maximum SUV did not differ between clinically active and inactive patients. In the visual analysis, all participants had at least 1 vascular site with inflammatory activity, with an uptake ≥2 in relation to the liver. The aortic arch was the most frequently involved site.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Conclusions</jats:title>

            <jats:p>This study showed that <jats:sup>18</jats:sup>F-FDG PET/CT in late acquisition is an effective imaging method to assess TA activity even in fully treated patients.</jats:p>

          </jats:sec>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Ramos2022b,

title = {Multimodality molecular imaging in arthropathy associated with multiple myeloma},

author = {CelsoDario Ramos and LudmilaSantiago Almeida and StephanPinheiro Macedo de Souza and FernandoVieira Pericole de Souza and Fabiano Reis},

doi = {10.4103/ijnm.ijnm_205_21},

issn = {0972-3919},

year  = {2022},

date = {2022-00-00},

urldate = {2022-00-00},

journal = {Indian J Nucl Med},

volume = {37},

number = {3},

publisher = {Medknow},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Carraro2021,

title = {Arcuate Nucleus Overexpression of NHLH2 Reduces Body Mass and Attenuates Obesity-Associated Anxiety/Depression-like Behavior},

author = {Rodrigo S. Carraro and Guilherme A. Nogueira and Davi Sidarta-Oliveira and Rodrigo S. Gaspar and Nathalia R. Dragano and Joseane Morari and Vanessa C. D. Bobbo and Eliana P. Araujo and Natalia F. Mendes and Ariane M. Zanesco and Natalia Tobar and Celso D. Ramos and Jéssica M. Toscaro and Marcio C. Bajgelman and Licio A. Velloso},

doi = {10.1523/jneurosci.0222-21.2021},

issn = {1529-2401},

year  = {2021},

date = {2021-12-01},

urldate = {2021-12-01},

journal = {J. Neurosci.},

volume = {41},

number = {48},

pages = {10004--10022},

publisher = {Society for Neuroscience},

abstract = {<jats:p>Nescient helix-loop-helix 2 (NHLH2) is a hypothalamic transcription factor that controls the expression of prohormone convertase 1/3, therefore having an impact on the processing of proopiomelanocortin and thus on energy homeostasis. Studies have shown that KO of<jats:italic>Nhlh2</jats:italic>results in increased body mass, reduced physical activity, and hypogonadism. In humans, a polymorphism of the<jats:italic>NHLH2</jats:italic>gene is associated with obesity; and in Prader–Willi syndrome, a condition characterized by obesity, hypogonadism and behavioral abnormalities, the expression of NHLH2 is reduced. Despite clinical and experimental evidence suggesting that NHLH2 could be a good target for the treatment of obesity, no previous study has evaluated the impact of NHLH2 overexpression in obesity. Here, in mice fed a high-fat diet introduced right after the arcuate nucleus intracerebroventricular injection of a lentivirus that promoted 40% increase in NHLH2, there was prevention of the development of obesity by a mechanism dependent on the reduction of caloric intake. When hypothalamic overexpression of NHLH2 was induced in previously obese mice, the beneficial impact on obesity-associated phenotype was even greater; thus, there was an 80% attenuation in body mass gain, reduced whole-body adiposity, increased brown adipose tissue temperature, reduced hypothalamic inflammation, and reduced liver steatosis. In this setting, the beneficial impact of hypothalamic overexpression of NHLH2 was a result of combined effects on caloric intake, energy expenditure, and physical activity. Moreover, the hypothalamic overexpression of NHLH2 reduced obesity-associated anxiety/depression behavior. Thus, we provide an experimental proof of concept supporting that hypothalamic NHLH2 is a good target for the treatment of obesity.</jats:p><jats:p><jats:bold>SIGNIFICANCE STATEMENT</jats:bold>Obesity is a highly prevalent medical condition that lacks an effective treatment. The main advance provided by this study is the demonstration of the beneficial metabolic and behavioral outcomes resulting from the overexpression of NHLH2 in the hypothalamus. When NHLH2 was overexpressed simultaneously with the introduction of a high-fat diet, there was prevention of obesity by a mechanism dependent on reduced caloric intake. Conversely, when NHLH2 was overexpressed in previously obese mice, there was reduction of the obese phenotype because of a combination of reduced caloric intake, increased physical activity, and increased thermogenesis. In addition, the overexpression of NHLH2 reduced anxiety/depression-like behavior. Thus, NHLH2 emerges as a potential target for the combined treatment of obesity and its associated anxiety/depression-like behavior.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Takahashi2021,

title = {Metabolic Volume Measurements in Multiple Myeloma},

author = {Maria Emilia Seren Takahashi and Irene Lorand-Metze and Carmino Antonio de Souza and Claudio Tinoco Mesquita and Fernando Amorim Fernandes and José Barreto Campello Carvalheira and Celso Dario Ramos},

doi = {10.3390/metabo11120875},

issn = {2218-1989},

year  = {2021},

date = {2021-12-00},

urldate = {2021-12-00},

journal = {Metabolites},

volume = {11},

number = {12},

publisher = {MDPI AG},

abstract = {<jats:p>Multiple myeloma (MM) accounts for 10–15% of all hematologic malignancies, as well as 20% of deaths related to hematologic malignant tumors, predominantly affecting bone and bone marrow. Positron emission tomography/computed tomography with 18F-fluorodeoxyglucose (FDG-PET/CT) is an important method to assess the tumor burden of these patients. It is often challenging to classify the extent of disease involvement in the PET scans for many of these patients because both focal and diffuse bone lesions may coexist, with varying degrees of FDG uptake. Different metrics involving volumetric parameters and texture features have been proposed to objectively assess these images. Here, we review some metabolic parameters that can be extracted from FDG-PET/CT images of MM patients, including technical aspects and predicting MM outcome impact. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) are volumetric parameters known to be independent predictors of MM outcome. However, they have not been adopted in clinical practice due to the lack of measuring standards. CT-based segmentation allows automated, and therefore reproducible, calculation of bone metabolic metrics in patients with MM, such as maximum, mean and standard deviation of the standardized uptake values (SUV) for the entire skeleton. Intensity of bone involvement (IBI) is a new parameter that also takes advantage of this approach with promising results. Other indirect parameters obtained from FDG-PET/CT images, such as visceral adipose tissue glucose uptake and subcutaneous adipose tissue radiodensity, may also be useful to evaluate the prognosis of MM patients. Furthermore, the use and quantification of new radiotracers can address different metabolic aspects of MM and may have important prognostic implications.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Pereira2021,

title = {Fixed 30 mCi (1110 MBq) 131I-iodine therapy in autonomously functioning nodules: Single toxic nodule as a predictive factor of success},

author = {Lívia Pereira and Cinthia Riguetto and Arnaldo Neto and Marcos Tambascia and Celso Ramos and Denise Zantut-Wittmann},

doi = {10.4103/wjnm.wjnm_150_20},

issn = {1607-3312},

year  = {2021},

date = {2021-10-00},

urldate = {2021-10-00},

journal = {World J Nucl Med},

volume = {20},

number = {04},

pages = {349--354},

publisher = {Georg Thieme Verlag KG},

abstract = {<jats:title>Abstract</jats:title><jats:p>Aims: The aim of this study is to evaluate the efficacy of a fixed 30 mCi (1110 MBq) 131I-iodine dose for the treatment of hyperthyroidism due to uninodular or multinodular toxic goiter and identify predictors of success. Materials and Methods: Fifty-nine patients diagnosed with nonautoimmune toxic goiter were treated with a fixed 30 mCi dose of 131I-iodine and were followed at a tertiary service between 2000 and 2016. The therapy was considered successful if the patient reached euthyroidism or hypothyroidism without needing an extra 131I-iodine dose or antithyroid drugs for at least 1 year after the radioiodine therapy (RIT). Results: Patients with a single toxic nodule were younger at diagnosis (52 vs. 63 years; P = 0.007), presented a shorter disease duration until RIT (2 vs. 3.5 years; P = 0.007), smaller total thyroid volume (20 vs. 82 cm3; P = 0.044), and lower pre-RIT thyroid uptake (P = 0.043) than patients with multinodular goiter. No significant difference was seen with antithyroid drug use, thyroid-stimulating hormone and free thyroxine level, and follow-up after RIT. After RIT, 47 patients (79.66%) met the success criteria, and 12 (20.33%) remained hyperthyroid. Among the success group, 32 (68.08%) reached euthyroidism, while 31.92% developed hypothyroidism after 1 year. Patients with single toxic nodules who achieved success after RIT presented smaller nodules (2.8 vs. 5.75 cm; P = 0.043), while the pre-RIT thyroid uptake was higher among patients with multinodular toxic goiter who achieved success after RIT (5.5% vs. 1.5%; P = 0.007). A higher success rate was observed among patients with a single toxic nodule than those with a toxic multinodular goiter (92.3% vs. 55%; P = 0.001), and a single toxic nodule presentation was found to be an independent predictor of success (P = 0.009). Conclusions: The fixed 30 mCi 131I-iodine dose was particularly effective in the group of patients with single autonomously functioning nodule rather than the group with multiple nodules. A single toxic nodule was an independent predictor of treatment success.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{deMoura2021,

title = {Docetaxel and Lidocaine Co-Loaded (NLC-in-Hydrogel) Hybrid System Designed for the Treatment of Melanoma},

author = {Ludmilla David de Moura and Lígia N. M. Ribeiro and Fabíola V. de Carvalho and Gustavo H. Rodrigues da Silva and Priscila C. Lima Fernandes and Sérgio Q. Brunetto and Celso D. Ramos and Lício A. Velloso and Daniele R. de Araújo and Eneida de Paula},

doi = {10.3390/pharmaceutics13101552},

issn = {1999-4923},

year  = {2021},

date = {2021-10-00},

urldate = {2021-10-00},

journal = {Pharmaceutics},

volume = {13},

number = {10},

publisher = {MDPI AG},

abstract = {<jats:p>Melanoma is the most aggressive skin carcinoma and nanotechnology can bring new options for its pharmacological treatment. Nanostructured lipid carriers (NLC) are ideal drug-delivery carriers for hydrophobic drugs, such as the antineoplastic docetaxel (DTX), and hybrid (NLC-in-hydrogel) systems are suitable for topical application. This work describes a formulation of NLCDTX in xanthan-chitosan hydrogel containing lidocaine (LDC) with anticancer and analgesia effects. The optimized nanoparticles encapsulated 96% DTX and rheological analysis revealed inherent viscoelastic properties of the hydrogel. In vitro assays over murine fibroblasts (NIH/3T3) and melanoma cells (B16-F10), human keratinocytes (HaCaT) and melanoma cells (SK-MEL-103) showed reduction of docetaxel cytotoxicity after encapsulation in NLCDTX and HGel-NLCDTX. Addition of LDC to the hybrid system (HGel-NLCDTX-LDC) increased cell death in tumor and normal cells. In vivo tests on C57BL/6J mice with B16-F10-induced melanoma indicated that LDC, NLCDTX, HGel-NLCDTX-LDC and NLCDTX + HGel-LDC significantly inhibited tumor growth while microPET/SPECT/CT data suggest better prognosis with the hybrid treatment. No adverse effects were observed in cell survival, weight/feed-consumption or serum biochemical markers (ALT, AST, creatinine, urea) of animals treated with NLCDTX or the hybrid system. These results confirm the adjuvant antitumor effect of lidocaine and endorse HGel-NLCDTX-LDC as a promising formulation for the topical treatment of melanoma.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Yoshizane2021,

title = {CT Images of Zebrafish for Preclinical Studies in a Micro PET/SPECT/CT Equipment},

author = {M.K. Yoshizane and S.Q. Brunetto and T.G. Parolari and C.V. Maurer-Morelli and C.D. Ramos},

doi = {10.1088/1748-0221/16/08/p08049},

issn = {1748-0221},

year  = {2021},

date = {2021-08-01},

urldate = {2021-08-01},

journal = {J. Inst.},

volume = {16},

number = {08},

publisher = {IOP Publishing},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid33636089,

title = {Simultaneous Imaging of Lung Perfusion and Glucose Metabolism in COVID-19 Pneumonia},

author = {Celso Dario Ramos and Alins P Fernandes and Stephan P M Souza and Mariana Fujiwara and Natalia Tobar and Sergio S J Dertkigil and Maria Emília S Takahashi and Eduardo S L Gonçales and Plinio Trabasso and Denise E Zantut-Wittmann},

doi = {10.1164/rccm.202007-2944IM},

issn = {1535-4970},

year  = {2021},

date = {2021-05-01},

urldate = {2021-05-01},

journal = {Am J Respir Crit Care Med},

volume = {203},

number = {9},

pages = {1186--1187},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Zanetti2021,

title = {Comparison of different fiducial markers to guide SPECT and CT image registration},

author = {T.C. Zanetti and S.Q. Brunetto and E.M. Souza and L.D.S. Sachinelli and C.D. Ramos and D.E. Zantut-Wittmann},

doi = {10.1088/1748-0221/16/05/t05003},

issn = {1748-0221},

year  = {2021},

date = {2021-05-01},

urldate = {2021-05-01},

journal = {J. Inst.},

volume = {16},

number = {05},

publisher = {IOP Publishing},

abstract = {<jats:title>Abstract</jats:title>

               <jats:p>Registration and fusion guided by the fiducial markers of

  SPECT and CT images acquired via distinct equipment is a common

  practice in several nuclear medicine centres. In this study, five

  different fiducial configurations were studied and compared for

  SPECT and CT image acquisitions: iodide-131 (<jats:sup>131</jats:sup>I) within a

  needle cap, <jats:sup>131</jats:sup>I associated with cotton, a lead and a ceramic

  aluminium sphere or mixed with an agarose solution. Fiducials that

  employed agarose mixtures presented the lowest <jats:italic>dpr</jats:italic> values

  (between 0.34 and 0.53 mm) and better homogeneous regions in both

  images to perform registration. In addition, this assembly exhibited

  the lowest global mean <jats:italic>dpr</jats:italic> and standard deviations in

  Gaussian adjustments. In comparison with the other configurations,

  the agarose <jats:italic>dpr</jats:italic> was statistically lower than that of

  cotton, ceramic aluminium and just <jats:sup>131</jats:sup>I for all the six

  landmarks. Despite its similarity with the lead sphere

  configuration, for five of the landmarks, agarose showed no

  artefacts in CT and more homogeneous regions of interest in SPECT

  images. In addition, agarose demonstrated great reproducibility to

  guide point-based registration processes.</jats:p>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{deSouza2021,

title = {Head-to-head comparison between 68Ga-PSMA and 18F-FDG-PET/CT in lymphomas: a preliminary analysis},

author = {Stephan Pinheiro Macedo de Souza and Natalia Tobar and Fernanda Frasson and Efrain Araujo Perini and Carmino A. de Souza and Marcia T. Delamain and Celso Dario Ramos},

doi = {10.1097/mnm.0000000000001465},

issn = {0143-3636},

year  = {2021},

date = {2021-00-00},

urldate = {2021-00-00},

volume = {42},

number = {12},

pages = {1355--1360},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

abstract = {<jats:sec>

            <jats:title>Purpose</jats:title>

            <jats:p>Isolated case reports mention the uptake of radiolabeled PSMA in lymphoma. However, it is not clear if the intensity of 68Ga-PSMA expression varies among different histological subtypes or if it correlates with 18F-FDG uptake. This study compared both tracers in patients with diverse lymphoma subtypes.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Methods</jats:title>

            <jats:p>Ten patients with biopsy-proven-lymphoma underwent 18F-FDG and 68Ga-PSMA-PET/CT (maximum time interval: 6 days). Lymphoma subtypes included Hodgkin’s lymphoma (HL, three patients) and aggressive and indolent non-Hodgkin’s lymphoma (NHL, seven patients). The intensity of PSMA uptake was classified visually as low, intermediate, or high, using blood pool, liver and parotid gland uptake as references. Maximum standardized-uptake value (SUVmax) of each affected site was measured in both sets of images.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Results</jats:title>

            <jats:p>FDG detected 59/59 involved sites in 10 patients and PSMA 47/59 sites in nine patients. PSMA uptake was generally low, regardless of the intensity of FDG uptake, but it was classified as intermediate in two patients. The median SUVmax varied from 2.0 (2.0–8.2) to 30.9 for FDG and from 1.7 (1.7–1.7) to 4.4 for PSMA, <jats:italic toggle="yes">P</jats:italic> < 0.0001. The primary lesion of one patient had a marked intralesional mismatch uptake pattern of the tracers, with areas of higher PSMA expression than FDG uptake, and vice-versa. A brain lesion was more easily identified with PSMA than with FDG images.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Conclusion</jats:title>

            <jats:p>HL and several NHL subtypes may present PSMA uptake. The intensity of PSMA expression is generally lower than that of FDG uptake and seems to present less variation among the different histological subtypes of lymphomas.</jats:p>

          </jats:sec>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Takahashi2021b,

title = {Intensity of bone involvement: a quantitative 18F-FDG PET/CT evaluation for monitoring outcome of multiple myeloma},

author = {Maria Emilia Seren Takahashi and Camila Mosci and Gislaine O. Duarte and Fernando V. Pericole and Konradin Metze and Irene G.H. Lorand-Metze and Celso D. Ramos},

doi = {10.1097/mnm.0000000000001470},

issn = {0143-3636},

year  = {2021},

date = {2021-00-00},

urldate = {2021-00-00},

volume = {42},

number = {12},

pages = {1375--1381},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

abstract = {<jats:sec>

            <jats:title>Purpose</jats:title>

            <jats:p>The parameter intensity of bone involvement (IBI) was recently proposed to quantitatively assess patients with multiple myeloma using <jats:sup>18</jats:sup>F-fluorodeoxyglucose-PET combined with computed tomography (<jats:sup>18</jats:sup>F-FDG PET/CT) images. Here, we aimed to calculate IBI variation (ΔIBI) between two consecutive PET/CT of the same patient and verified its relationship with a subjective visual analysis of the images and with clinical outcome.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Methods</jats:title>

            <jats:p>Consecutive whole-body <jats:sup>18</jats:sup>F-FDG PET/CT performed to assess the outcomes of 29 patients diagnosed with multiple myeloma were retrospectively evaluated. ΔIBI was calculated after bone segmentation, using liver standardized uptake value as a threshold to determine metabolically active volumes in the skeleton. For each pair of consecutive PET/CTs, two nuclear medicine physicians classified visually the most recent image as PET-remission, PET-progression or PET-stable when compared to the previous examination.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Results</jats:title>

            <jats:p>The lowest ΔIBI was –1.27 and the highest was 0.29. PET-remission was related to ΔIBI <0 (median = –0.10; –1.27 to +0.03), while PET-progression was related to ΔIBI >0 (median = 0.02; –0.07 to +0.29). ΔIBI around zero was found in images classified as PET-stable (median = 0.00; –0.08 to +0.06). Significant difference in ΔIBI was found between the three groups. Multivariate stepwise analysis showed that IBI value at diagnostic PET/CT, serum calcium and percentage of plasma cells in the bone marrow are independent prognostic factors.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Conclusion</jats:title>

            <jats:p>Delta IBI provides quantitative data for variations of <jats:sup>18</jats:sup>F-FDG uptake in the bone marrow during the follow-up of the patients. In addition, higher IBI values at diagnosis are associated with a higher risk of patient’s death.</jats:p>

          </jats:sec>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Brito2020,

title = {Radium-223 as an Approved Modality for Treatment of Bone Metastases},

author = {Ana Emília Brito and Elba Etchebehere},

doi = {10.1053/j.semnuclmed.2019.11.005},

issn = {0001-2998},

year  = {2020},

date = {2020-03-00},

urldate = {2020-03-00},

journal = {Seminars in Nuclear Medicine},

volume = {50},

number = {2},

pages = {177--192},

publisher = {Elsevier BV},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Camacho2019,

title = {Validation of a Multifocal Segmentation Method for Measuring Metabolic Tumor Volume in Hodgkin Lymphoma},

author = {Mariana R. Camacho and Elba Etchebehere and Natalia Tardelli and Marcia T. Delamain and Aline F.A. Vercosa and Maria E.S. Takahashi and Sergio Q. Brunetto and Irene G.H.L. Metze and Cármino A. Souza and Juliano J. Cerci and Celso D. Ramos},

doi = {10.2967/jnmt.119.231118},

issn = {1535-5675},

year  = {2020},

date = {2020-03-00},

urldate = {2020-03-00},

journal = {J. Nucl. Med.                Technol.},

volume = {48},

number = {1},

pages = {30--35},

publisher = {Society of Nuclear Medicine},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Mosci2020,

title = {99mTc-sestamibi SPECT/CT and 18F-FDG-PET/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma},

author = {Camila Mosci and Fernando V. Pericole and Gislaine B. Oliveira and Marcia T. Delamain and Maria E.S. Takahashi and José Barreto C. Carvalheira and Elba C.S.C. Etchebehere and Allan O. Santos and Eliana C. M. Miranda and Mariana C.L. Lima and Barbara J. Amorim and Carmino A. de Souza and Irene Lorand-Metze and Celso D. Ramos},

doi = {10.1097/mnm.0000000000001259},

issn = {0143-3636},

year  = {2020},

date = {2020-00-00},

urldate = {2020-00-00},

volume = {41},

number = {10},

pages = {1081--1088},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

abstract = {<jats:sec>

            <jats:title>Purpose</jats:title>

            <jats:p>

                                 <jats:sup>18</jats:sup>F-fluorodeoxiglucose (<jats:sup>18</jats:sup>F-FDG)-PET/CT has been widely used to evaluate multiple myeloma. <jats:sup>99m</jats:sup>Tc-sestamibi (MIBI) scintigraphy has also been proposed for assessing multiple myeloma, but its use with state-of-the-art single-photon emission computed tomography/computed tomography (SPECT/CT) technology has not been fully evaluated.This study aimed to compare these two imaging modalities in multiple myeloma staging.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Materials and methods</jats:title>

            <jats:p>Sixty-two patients with recently diagnosed multiple myeloma were submitted to whole-body <jats:sup>18</jats:sup>F-FDG-PET/CT and whole-body MIBI scans plus SPECT/CT of the chest and abdomen/pelvis. Number of focal lesions, contiguous soft tissue involvement (CSTI), extramedullary lesions (EMLs) and diffuse bone marrow (BM) involvement were recorded.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Results</jats:title>

            <jats:p>PET/CT was positive in 59 patients (95%) and MIBI SPECT/CT in 58 (93%) (<jats:italic toggle="yes">P</jats:italic> = 0.69). MIBI detected more diffuse bone marrow involvement than PET/CT (respectively 78 vs. 58% of the patients), while PET/CT demonstrated more focal lesions than MIBI SPECT/CT (81 vs. 54% of the patients) (<jats:italic toggle="yes">P</jats:italic> = 0.002). PET/CT detected EMLs in four subjects and MIBI in one subject. CSTI was found in 28 (45%) and 23 (37%) patients on PET/CT and MIBI images, respectively (<jats:italic toggle="yes">P</jats:italic> = 0.36). Three patients with lytic lesions and no FDG uptake were MIBI positive, and two subjects with lytic lesions without MIBI uptake were FDG positive.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Conclusion</jats:title>

            <jats:p>MIBI SPECT/CT performs similarly to <jats:sup>18</jats:sup>F-FDG-PET/CT in identifying sites of active disease in multiple myeloma staging. MIBI is more efficient than FDG for detecting the diffuse involvement of bone marrow but less efficient for detecting focal lesions. Some patients presented a ‘mismatch’ pattern of FDG/MIBI uptake.</jats:p>

          </jats:sec>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Takahashi2020,

title = {Computed tomography–based skeletal segmentation for quantitative PET metrics of bone involvement in multiple myeloma},

author = {Maria E.S. Takahashi and Camila Mosci and Edna M. Souza and Sérgio Q. Brunetto and Cármino de Souza and Fernando V. Pericole and Irene Lorand-Metze and Celso D. Ramos},

doi = {10.1097/mnm.0000000000001165},

issn = {0143-3636},

year  = {2020},

date = {2020-00-00},

urldate = {2020-00-00},

volume = {41},

number = {4},

pages = {377--382},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

abstract = {<jats:sec>

            <jats:title>Purpose</jats:title>

            <jats:p>Quantifications in nuclear medicine are occasionally limited by the lack of standardization for defining volumes of interest (VOIs) on functional images. In the present article, we propose the use of computed tomography (CT)–based skeletal segmentation to determine anatomically the VOI in order to calculate quantitative parameters of fluorine 18 <jats:italic toggle="yes">fluorodeoxyglucose</jats:italic> (<jats:sup>18</jats:sup>F-FDG) PET/CT images from patients with multiple myeloma.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Methods</jats:title>

            <jats:p>We evaluated 101 whole-body <jats:sup>18</jats:sup>F-FDG PET/CTs of 58 patients with multiple myeloma. An initial subjective visual analysis of the PET images was used to classify the bone involvement as negative/mild, moderate, or marked. Then, a fully automated CT–based segmentation of the skeleton was performed on PET images. The maximum, mean, and SD of the standardized uptake values (SUV<jats:sub>max</jats:sub>, SUV<jats:sub>mean</jats:sub>, and SD<jats:sub>SUV</jats:sub>) were calculated for bone tissue and compared with the visual analysis.</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Results</jats:title>

            <jats:p>Forty-five (44.5%), 32 (31.7%), and 24 (23.8%) PET images were, respectively, classified as negative/mild, moderate, or marked bone involvement. All quantitative parameters were significantly related to the visual assessment of bone involvement. This association was stronger for the SUV<jats:sub>mean</jats:sub> [odds ratio (OR): 10.52 (95% confidence interval (CI), 5.68–19.48); <jats:italic toggle="yes">P</jats:italic> < 0.0001] and for the SD<jats:sub>SUV</jats:sub> [OR: 5.58 (95% CI, 3.31–9.42); <jats:italic toggle="yes">P</jats:italic> < 0.001) than for the SUV<jats:sub>max</jats:sub> [OR: 1.01 (95% CI, 1.003–1.022); <jats:italic toggle="yes">P</jats:italic> = 0.003].</jats:p>

          </jats:sec>

          <jats:sec>

            <jats:title>Conclusion</jats:title>

            <jats:p>CT–based skeletal segmentation allows for automated and therefore reproducible calculation of PET quantitative parameters of bone involvement in patients with multiple myeloma. Using this method, the SUV<jats:sub>mean</jats:sub> and its respective SD correlated better with the visual analysis of <jats:sup>18</jats:sup>F-FDG PET images than SUVmax. Its value in staging and evaluating therapy response needs to be evaluated.</jats:p>

          </jats:sec>},

keywords = {},

pubstate = {published},

tppubtype = {article}

}